Therapeutic use of Glucagon or a combination comprising the same
A combination of modified glucagon peptides and therapeutic agents targets glucagon receptors to treat metabolic syndrome, addressing side effects by promoting fat breakdown and stabilizing glucose levels, providing an effective treatment for obesity and diabetes.
Patent Information
- Application Number
- KR1020260217021
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-10-04
- Filing Date
- 2026-11-03
- Publication Date
- 2026-11-17
AI Technical Summary
Current treatments for metabolic syndrome, such as obesity, diabetes, and related conditions, often cause side effects like weight gain, hypoglycemia, and cardiovascular issues due to the opposing actions of insulin and glucagon, and there is a need for a drug that can effectively manage these conditions without such adverse effects.
A combination of a substance with activity towards glucagon receptors, such as modified glucagon peptides or derivatives, and compounds with therapeutic activity against metabolic syndrome, including GLP-1 receptor agonists and other therapeutic agents, is administered to individuals to prevent or treat conditions like obesity, diabetes, and metabolic syndrome.
The combination addresses metabolic syndrome by promoting fat breakdown, reducing appetite, and stabilizing blood glucose levels, thereby effectively treating conditions like obesity and diabetes without the side effects associated with existing treatments.
Smart Images

Figure PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a compound or substance having glucagon activity; or a combination comprising a compound or substance having glucagon activity and a compound or substance having therapeutic activity for metabolic syndrome, and the therapeutic use thereof. Background Technology
[0003] Recently, due to economic development and changes in dietary habits, the incidence of metabolic syndrome-related diseases, including various conditions such as obesity, hyperlipidemia, hypertension, arteriosclerosis, hyperinsulinemia, diabetes, and liver disease, is rapidly increasing. While these diseases can occur individually, they are generally closely related and mostly occur accompanied by various symptoms.
[0004] Overweight and obesity increase blood pressure and cholesterol levels, causing the onset or worsening of various diseases such as heart disease, diabetes, and arthritis. Furthermore, overweight and obesity are major factors that increase the incidence of arteriosclerosis, hypertension, hyperlipidemia, or heart disease not only in adults but also in children and adolescents.
[0005] Obesity is surprisingly difficult to treat, because it is a complex disease involving the mechanisms of appetite control and energy metabolism. Therefore, in order to treat obesity, not only the patient's own efforts but also methods to treat the abnormal mechanisms of action related to appetite control and energy metabolism must be carried out simultaneously, so efforts to develop drugs capable of treating the abnormal mechanisms of action are continuing.
[0006] As a result of the aforementioned efforts, obesity treatments such as Rimonabant (Sanofi-Aventis), Sibutramine (Abbott), Contrave (Takeda), and Orlistat (Roche) were developed, but they had the disadvantage of exhibiting fatal side effects or having insufficient efficacy in treating obesity. For example, it was reported that Rimonabant exhibited central nervous system side effects, Sibutramine and Contrave exhibited cardiovascular side effects, and Orlistat only showed a weight loss effect of about 4 kg when taken for one year.
[0007] Meanwhile, glucagon is produced in the pancreas when blood glucose levels begin to drop due to causes such as drug treatment, disease, or hormone or enzyme deficiencies. Glucagon signals the liver to break down glycogen to release glucose and plays a role in raising blood glucose levels to normal levels. Furthermore, in addition to its blood glucose-raising effect, glucagon has been reported to exhibit anti-obesity effects by suppressing appetite and activating hormone-sensitive lipase in fat cells to promote fat breakdown. However, the use of glucagon as a therapeutic agent has been limited due to its low solubility and precipitation at neutral pH.
[0008] Glucagon-like peptide-1 (GLP-1), one of these glucagon derivatives, is a substance currently under development as a treatment to reduce hyperglycemia in diabetic patients. GLP-1 has the functions of promoting insulin synthesis and secretion, inhibiting glucagon secretion, suppressing gastric hunger, enhancing glucose utilization, and inhibiting food intake.
[0009] Exendin-4, which is produced from lizard venom and has approximately 50% amino acid homology with GLP-1, is also known to activate GLP-1 receptors and reduce hyperglycemia in diabetic patients (J Biol Chem. 1992 Apr 15;267(11):7402-5.). However, it has been reported that obesity treatment drugs containing the above-mentioned GLP-1 or exendin-4 have the problem of causing side effects such as vomiting and nausea.
[0011] Compounds or substances having therapeutic activity against glucagon and metabolic syndrome are generally known to have opposing effects and have been used as treatments for different conditions. In particular, Korean Patent Publication No. 10-2017-0023066 discloses a method of antagonizing glucagon action by blocking glucagon receptors with antagonistic antigen proteins, while simultaneously treating diabetes by supplementing insulin.
[0012] In other words, since insulin and glucagon perform opposing roles in the body, there is no known drug treatment that administers them together. Meanwhile, when various treatments for metabolic syndrome are administered to patients, there is a risk of side effects such as weight gain, overdose, and hypoglycemia. The problem to be solved
[0014] One object of the present invention is to relate to a substance having activity toward glucagon receptors or a combination thereof, and a compound or substance having therapeutic activity toward metabolic syndrome.
[0015] Another objective of the present invention is to provide a combination, pharmaceutical composition, or kit comprising a substance having activity toward glucagon receptors or a combination thereof and a compound or substance having therapeutic activity toward metabolic syndrome, specifically a combination, pharmaceutical composition, or kit for the prevention or treatment of metabolic syndrome.
[0016] Another objective of the present invention is to provide a method for preventing or treating metabolic syndrome, comprising the step of administering a substance having activity toward glucagon receptors or a conjugate thereof, and a compound or substance having therapeutic activity toward metabolic syndrome, to an individual in need thereof.
[0017] Another objective of the present invention is to provide a composition comprising a peptide having activity toward a glucagon receptor or a conjugate containing the same, specifically a pharmaceutical composition for the prevention or treatment of metabolic syndrome, hypoglycemia, or congenital hyperinsulinism.
[0018] Another objective of the present invention is to provide a kit comprising a peptide having activity against a glucagon receptor or a conjugate containing the same, specifically a kit for the prevention or treatment of metabolic syndrome, hypoglycemia, or congenital hyperinsulinism.
[0019] Another object of the present invention is to provide a method for preventing or treating congenital hyperinsulinism, comprising the step of administering a peptide having activity for the glucagon receptor, or a conjugate containing the same, or a composition containing the same, to an individual in need thereof.
[0020] Another objective of the present invention is to provide the use of a peptide having activity toward the glucagon receptor, a conjugate containing the same, or a composition containing the same in the manufacture of a drug for the prevention or treatment of congenital hyperinsulinism.
[0021] Another object of the present invention is to provide a method for preventing or treating hypoglycemia, comprising the step of administering a peptide having activity for the glucagon receptor, or a conjugate containing the same, or a composition containing the same, to an individual in need thereof.
[0022] Another objective of the present invention is to provide a use of a peptide having activity toward the glucagon receptor, a conjugate containing the same, or a composition containing the same in the manufacture of a drug for the prevention or treatment of hypoglycemia.
[0023] Another object of the present invention is to provide a method for preventing or treating obesity, comprising the step of administering a peptide or isolated conjugate having activity toward a glucagon receptor, or a composition containing the same, to an individual in need thereof.
[0024] Another objective of the present invention is to provide a use for a peptide or isolated conjugate having activity against a glucagon receptor, or said composition, in the manufacture of a drug (or pharmaceutical composition) for the prevention or treatment of obesity.
[0025] Another object of the present invention is to provide a method for preventing or treating metabolic syndrome, comprising the step of administering a peptide or isolated conjugate having activity for glucagon receptors, or a composition containing the same, to an individual in need thereof.
[0026] Another objective of the present invention is to provide a use for a peptide or isolated conjugate having activity against a glucagon receptor, or said composition, in the manufacture of a drug (or pharmaceutical composition) for the prevention or treatment of metabolic syndrome. means of solving the problem
[0027] One embodiment of the present invention is a combination comprising a substance or a conjugate thereof having activity toward glucagon receptors and a compound or substance having therapeutic activity toward metabolic syndrome.
[0029] In one embodiment, the present invention relates to a therapeutic use of a substance or a conjugate thereof having activity toward glucagon receptors and a compound or substance having therapeutic activity toward metabolic syndrome.
[0031] In the preceding embodiment, the present invention relates to a combination, pharmaceutical composition, or kit comprising a substance having activity toward glucagon receptors or a combination thereof and a compound or substance having therapeutic activity toward metabolic syndrome, specifically a combination, pharmaceutical composition, or kit for the prevention or treatment of metabolic syndrome.
[0033] In the preceding embodiment(s), the substance having activity toward the glucagon receptor is characterized as being natural glucagon, an agonist thereof, or a derivative thereof.
[0035] In the preceding specific examples, the derivative of natural glucagon is characterized by having one or more amino acids modified from natural glucagon, wherein the modification is a modification selected from the group consisting of substitution, addition, deletion, modification, and combinations thereof.
[0037] In the preceding embodiment(s), the substance having activity toward the glucagon receptor is characterized as being a peptide comprising the amino acid sequence of the following general formula 1:
[0039] X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-X24-WL-X27-X28-X29-X30 (General Formula 1, Sequence No.: 45)
[0041] In the above formula,
[0042] X1 is histidine (H), desamino-histidyl, N-dimethyl-histidyl, beta-hydroxy imidazopropionyl, 4-imidazoacetyl, beta-carboxy imidazopropionyl, tryptophan (W), or tyrosine (Y), or is absent;
[0043] X2 is alpha-methyl-glutamic acid, Aib (aminoisobutyric acid), D-alanine, glycine (G), Sar (N-methylglycine), serine (S), or D-serine;
[0044] X7 is threonine (T), valine (V), or cysteine (C);
[0045] X10 is tyrosine (Y) or cysteine (C);
[0046] X12 is lysine (K) or cysteine (C);
[0047] X13 is tyrosine (Y) or cysteine (C);
[0048] X14 is leucine (L) or cysteine (C);
[0049] X15 is aspartic acid (D), glutamic acid (E), or cysteine (C);
[0050] X16 is glutamic acid (E), aspartic acid (D), serine (S), alpha-methylglutamic acid, or cysteine (C), or is absent;
[0051] X17 is aspartic acid (D), glutamine (Q), glutamic acid (E), lysine (K), arginine (R), serine (S), cysteine (C), or valine (V), or is absent;
[0052] X18 is alanine (A), aspartic acid (D), glutamic acid (E), arginine (R), valine (V), or cysteine (C), or is absent;
[0053] X19 is alanine (A), arginine (R), serine (S), valine (V), or cysteine (C), or is absent;
[0054] X20 is lysine (K), histidine (H), glutamine (Q), aspartic acid (D), arginine (R), alpha-methylglutamic acid, or cysteine (C), or is absent;
[0055] X21 is aspartic acid (D), glutamic acid (E), leucine (L), valine (V), or cysteine (C), or is absent;
[0056] X23 is isoleucine (I), valine (V), or arginine (R), or is absent;
[0057] X24 is valine (V), arginine (R), alanine (A), cysteine (C), glutamic acid (E), lysine (K), glutamine (Q), alpha-methylglutamic acid, or leucine (L), or is absent;
[0058] X27 is isoleucine (I), valine (V), alanine (A), lysine (K), methionine (M), glutamine (Q), or arginine (R), or is absent;
[0059] X28 is glutamine (Q), lysine (K), asparagine (N), or arginine (R), or is absent;
[0060] X29 is lysine (K), alanine (A), glycine (G), or threonine (T), or is absent;
[0061] X30 is cysteine (C) or non-existent
[0062] (However, cases where the amino acid sequence of the above General Formula 1 is identical to SEQ ID NO: 1 are excluded).
[0064] In the preceding specific examples, in the above general formula 1,
[0065] X1 is histidine (H), tryptophan (W), or tyrosine (Y), or is absent;
[0066] X2 is serine (S) or Aib (aminoisobutyric acid);
[0067] X7 is threonine (T), valine (V), or cysteine (C);
[0068] X10 is tyrosine (Y) or cysteine (C);
[0069] X12 is lysine (K) or cysteine (C);
[0070] X13 is tyrosine (Y) or cysteine (C);
[0071] X14 is leucine (L) or cysteine (C);
[0072] X15 is aspartic acid (D) or cysteine (C);
[0073] X16 is glutamic acid (E), serine (S), or cysteine (C);
[0074] X17 is aspartic acid (D), glutamic acid (E), lysine (K), arginine (R), serine (S), cysteine (C), or valine (V);
[0075] X18 is aspartic acid (D), glutamic acid (E), arginine (R), or cysteine (C);
[0076] X19 is alanine (A) or cysteine (C);
[0077] X20 is glutamine (Q), aspartic acid (D), lysine (K), or cysteine (C);
[0078] X21 is aspartic acid (D), glutamic acid (E), leucine (L), valine (V), or cysteine (C);
[0079] X23 is isoleucine (I), valine (V), or arginine (R);
[0080] X24 is valine (V), arginine (R), alanine (A), glutamic acid (E), lysine (K), glutamine (Q), or leucine (L);
[0081] X27 is isoleucine (I), valine (V), alanine (A), methionine (M), glutamine (Q) or arginine (R);
[0082] X28 is glutamine (Q), lysine (K), asparagine (N), or arginine (R);
[0083] X29 is threonine (T);
[0084] X30 is characterized by being cysteine (C) or being absent.
[0086] In the preceding specific examples, in the above general formula 1
[0087] X1 is histidine (H), tryptophan (W), or tyrosine (Y);
[0088] X2 is serine (S) or Aib (aminoisobutyric acid);
[0089] X7 is cysteine (C), threonine (T), or valine (V);
[0090] X10 is tyrosine (Y) or cysteine (C);
[0091] X12 is lysine (K) or cysteine (C);
[0092] X13 is tyrosine (Y) or cysteine (C);
[0093] X14 is leucine (L) or cysteine (C);
[0094] X15 is aspartic acid (D) or cysteine (C);
[0095] X16 is glutamic acid (E), serine (S), or cysteine (C);
[0096] X17 is glutamic acid (E), lysine (K), arginine (R), cysteine (C), or valine (V);
[0097] X18 is arginine (R) or cysteine (C);
[0098] X19 is alanine (A) or cysteine (C);
[0099] X20 is glutamine (Q) or lysine (K);
[0100] X21 is aspartic acid (D), glutamic acid (E), valine (V), or cysteine (C);
[0101] X23 is valine (V);
[0102] X24 is valine (V) or glutamine (Q);
[0103] X27 is methionine (M);
[0104] X28 is asparagine (N) or arginine (R);
[0105] X29 is threonine (T);
[0106] X30 is characterized by being cysteine (C) or being absent.
[0108] In the preceding specific examples,
[0109] In the above general formula 1
[0110] X1 is tyrosine (Y);
[0111] X2 is Aib (aminoisobutyric acid);
[0112] X7 is cysteine (C), threonine (T), or valine (V);
[0113] X10 is tyrosine (Y) or cysteine (C);
[0114] X12 is Lee Sin (K);
[0115] X13 is tyrosine (Y) or cysteine (C);
[0116] X14 is leucine (L) or cysteine (C);
[0117] X15 is aspartic acid (D) or cysteine (C);
[0118] X16 is glutamic acid (E), serine (S), or cysteine (C);
[0119] X17 is lysine (K), arginine (R), cysteine (C), or valine (V);
[0120] X18 is arginine (R) or cysteine (C);
[0121] X19 is alanine (A) or cysteine (C);
[0122] X20 is glutamine (Q) or lysine (K);
[0123] X21 is aspartic acid (D), glutamic acid (E), or cysteine (C);
[0124] X23 is valine (V);
[0125] X24 is glutamine (Q);
[0126] X27 is methionine (M);
[0127] X28 is asparagine (N) or arginine (R);
[0128] X29 is threonine (T);
[0129] X30 is characterized by being cysteine (C) or being absent.
[0130] In the preceding specific examples, in the above general formula 1
[0131] X1 is histidine (H), tryptophan (W), or tyrosine (Y), or is absent;
[0132] X2 is serine (S) or Aib (aminoisobutyric acid);
[0133] X7 is threonine (T), valine (V), or cysteine (C);
[0134] X10 is tyrosine (Y) or cysteine (C);
[0135] X12 is lysine (K) or cysteine (C);
[0136] X13 is tyrosine (Y) or cysteine (C);
[0137] X14 is leucine (L) or cysteine (C);
[0138] X15 is aspartic acid (D) or cysteine (C);
[0139] X16 is glutamic acid (E), serine (S), or cysteine (C);
[0140] X17 is aspartic acid (D), glutamic acid (E), lysine (K), arginine (R), serine (S), cysteine (C), or valine (V);
[0141] X18 is aspartic acid (D), glutamic acid (E), arginine (R), or cysteine (C);
[0142] X19 is alanine (A) or cysteine (C);
[0143] X20 is glutamine (Q), aspartic acid (D), or lysine (K);
[0144] X21 is aspartic acid (D) or glutamic acid (E);
[0145] X23 is valine (V);
[0146] X24 is valine (V) or glutamine (Q);
[0147] X27 is isoleucine (I) or methionine (M);
[0148] X28 is asparagine (N) or arginine (R);
[0149] X29 is threonine (T);
[0150] X30 is characterized by being cysteine (C) or being absent.
[0152] In the preceding specific examples, in the above general formula 1
[0153] X1 is tyrosine (Y);
[0154] X2 is Aib (aminoisobutyric acid);
[0155] X7 is threonine (T);
[0156] X10 is tyrosine (Y);
[0157] X12 is Lee Sin (K);
[0158] X13 is tyrosine (Y);
[0159] X14 is leucine (L);
[0160] X15 is aspartic acid (D) or cysteine (C);
[0161] X16 is glutamic acid (E), serine (S), or cysteine (C);
[0162] X17 is lysine (K) or arginine (R);
[0163] X18 is arginine(R);
[0164] X19 is alanine (A);
[0165] X20 is glutamine (Q), cysteine (C), or lysine (K);
[0166] X21 is aspartic acid (D), cysteine (C), valine (V), or glutamic acid (E);
[0167] X23 is valine (V) or arginine (R);
[0168] X24 is glutamine (Q) or leucine (L);
[0169] X27 is methionine (M);
[0170] X28 is asparagine (N) or arginine (R);
[0171] X29 is threonine (T);
[0172] X30 is characterized by non-existence.
[0174] In the preceding specific examples, the peptide is characterized as being a peptide comprising the amino acid sequence of the following general formula 2.
[0176] Y-Aib-QGTF-X7-SD-X10-S-X12-YL-X15-X16-X17-RA-X20-X21-FV-X24-WLMNT-X30 (General Formula 2, Sequence No.: 46)
[0178] In the above general formula 2
[0179] X7 is threonine (T), valine (V), or cysteine (C);
[0180] X10 is tyrosine (Y) or cysteine (C);
[0181] X12 is lysine (K) or cysteine (C);
[0182] X15 is aspartic acid (D) or cysteine (C);
[0183] X16 is glutamic acid (E) or serine (S);
[0184] X17 is lysine (K) or arginine (R);
[0185] X20 is glutamine (Q) or lysine (K);
[0186] X21 is aspartic acid (D) or glutamic acid (E);
[0187] X24 is valine (V) or glutamine (Q);
[0188] X30 is cysteine (C) or is absent.
[0190] In the preceding specific examples, the peptide is characterized by having a pI different from 6.8, which is the pI of natural glucagon.
[0192] In the preceding embodiment(s), each of the amino acids of at least one amino acid pair among the amino acid pairs of X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20 and X24, and X24 and X28 of general formula 1 or 2 is substituted with glutamic acid or lysine capable of forming a ring.
[0194] In the preceding specific examples, each of the amino acids of the X12 and X16 amino acid pair of general formula 1 or 2, the X16 and X20 amino acid pair, or the X17 and X21 amino acid pair is substituted with glutamic acid or lysine capable of forming a ring.
[0196] In the preceding specific example(s), the above general formula 1 is characterized by forming a ring between each amino acid in at least one amino acid pair among the amino acid pairs of X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20 and X24, and X24 and X28.
[0198] In the preceding specific example(s), the C-terminus of the peptide is characterized by being amidated.
[0200] In the preceding specific examples, the C-terminus of the peptide is characterized as not being modified.
[0202] In the preceding specific examples, the peptide is characterized as being a derivative of natural glucagon capable of activating glucagon receptors.
[0204] In the preceding specific examples, the peptide is characterized by comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 44.
[0206] In the preceding embodiment(s), the peptide is characterized by comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 13, 15 and 36 to 44.
[0208] In the preceding specific example(s), the peptide is characterized by comprising the amino acid sequence of SEQ ID NO: 37.
[0210] In the preceding specific examples, the conjugate is characterized in that a biocompatible material portion is bound to a substance having activity toward a glucagon receptor.
[0212] In the preceding specific examples, the substance having activity toward the glucagon receptor is in the form of a peptide, characterized in that a biocompatible material portion is attached to a peptide portion having activity toward the glucagon receptor.
[0214] In the preceding embodiment(s), the biocompatible material part is characterized by being selected from the group consisting of polymers, fatty acids, cholesterol, albumin and fragments thereof, albumin binding substances, polymers of repeating units of specific amino acid sequences, antibodies, antibody fragments, FcRn binding substances, in vivo connective tissue or derivatives thereof, nucleotides, fibronectin, transferrin, sugars, heparin, and elastin.
[0216] In the preceding embodiment(s), the polymer is characterized by being selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.
[0218] In the preceding specific examples, the FcRn binding material is characterized as being a polypeptide comprising an immunoglobulin Fc region.
[0220] In the preceding specific examples, the substance having activity for the glucagon receptor and the biocompatible material part are connected to each other through a linker.
[0222] In the preceding embodiment(s), the linker is characterized by being selected from the group consisting of peptides, fatty acids, sugars, high molecular weight polymers, low molecular weight compounds, nucleotides, and combinations thereof.
[0224] In the preceding embodiment(s), the polymer is characterized by being selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.
[0226] In the preceding specific examples, the linker is characterized as being polyethylene glycol.
[0228] In the preceding embodiment(s), the immunoglobulin Fc region is characterized by being non-glycosylated.
[0230] In the preceding embodiment(s), the immunoglobulin Fc region is characterized by being selected from the group consisting of (a) a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain; (b) a CH1 domain and a CH2 domain; (c) a CH1 domain and a CH3 domain; (d) a CH2 domain and a CH3 domain; (e) a combination of one or more domains among the CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain with an immunoglobulin hinge region or a part of a hinge region; and (f) a dimer of each domain of the heavy chain invariant region and the light chain invariant region.
[0232] In the preceding specific examples, the polypeptide containing the immunoglobulin Fc region is characterized in that it is in a dimeric form.
[0234] In the preceding specific examples, the immunoglobulin Fc region is characterized as being a derivative of natural Fc in which a site capable of forming disulfide bonds is removed, some amino acids at the N-terminus of natural Fc are removed, a methionine residue is added to the N-terminus of natural Fc, a complement binding site is removed, or an ADCC (antibody dependent cell mediated cytotoxicity) site is removed.
[0236] In the preceding specific example(s), the immunoglobulin Fc region is characterized as being an Fc region derived from an immunoglobulin selected from the group consisting of IgG, IgA, IgD, IgE, and IgM.
[0238] In the preceding specific example(s), the immunoglobulin Fc region is characterized as being an IgG4 Fc region.
[0240] In the preceding embodiment(s), the immunoglobulin Fc region is characterized as being a non-glycosylated Fc region derived from human IgG4.
[0242] In the preceding specific examples, the linker is characterized by being connected to a cysteine residue of a peptide having activity toward the glucagon receptor.
[0244] In the preceding embodiment(s), the linker of the conjugate is characterized by being connected to the peptide portion and the biocompatible material portion by a covalent bond formed by reacting, respectively, with one end of the linker reacting with an amine group or a thiol group of the biocompatible material portion and with the other end of the linker reacting with an amine group or a thiol group of the peptide portion having activity for a glucagon receptor.
[0246] In the preceding specific examples, the compound or substance having therapeutic activity for metabolic syndrome is an insulin secretion peptide, a GLP-1 (glucagon-like peptide-1) receptor agonist, a leptin receptor agonist, a DPP-IV (dipeptidyl peptidase-IV) inhibitor, a Y5 receptor antagonist, an MCH (Melanin-concentrating hormone) receptor antagonist, a Y2 / 4 receptor agonist, an MC3 / 4 (Melanocortin 3 / 4) receptor agonist, a gastric / pancreatic lipase inhibitor, a 5HT2c (5-hydroxytryptamine receptor 2C) agonist, a G protein-coupled agonist, a β3A receptor agonist, an Amylin receptor agonist, a Ghrelin antagonist, a Ghrelin receptor Antagonists, PPARα (peroxisome proliferator-activated receptor alpha) agonists, PPARδ (peroxisome proliferator-activated receptor delta) agonists, FXR (farnesoid X receptor) agonists, acetyl-CoA carboxylase inhibitors, peptide YY, CCK (Cholecystokinin), Xenin, glicentin, obestatin, secretin, nesfatin, insuin, and GIP (glucose-dependent insulinotropic peptide), biguanides, sulfonylureas, meglitinide, thiazolidinedione (TZD), and SGLT2 (sodium-glucose cotransporter) inhibitor,It is characterized by being selected from the group consisting of and α-glucosidase inhibitors.
[0248] In the preceding specific examples, the compound or substance having therapeutic activity against metabolic syndrome is characterized as being a GLP-1 (glucagon-like peptide-1) receptor agonist.
[0250] In the preceding specific example(s), the GLP-1 (glucagon-like peptide-1) receptor agonist is characterized as being any one selected from the group consisting of exenatide, lixisenatide, dulaglutide, liraglutide, semaglutide, albiglutide, and taspoglutide.
[0252] In the preceding embodiment(s), the DPP-4 inhibitor is any one selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin, Trayenta®), anagliptin, teneligliptin, trelagliptin, gemigliptin, omagliliptin, evogliptin, and deutogliliptin; and the SGLT2 (sodium-glucose cotransporter) inhibitor is any one selected from the group consisting of empagliflozin, dapagliflozin, canagliflozin, remogliflozin, remogliflozin etabonate, sergliflozin, ipragliflozin, topogliflozin, luceogliflozin, and ertugliflozin.
[0254] In the preceding embodiment(s), the metabolic syndrome is characterized by being selected from the group consisting of impaired glucose tolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, nonalcoholic steatohepatitis (NASH), arteriosclerosis due to dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease (coronary artery heart disease), and stroke.
[0256] Another embodiment of the present invention is a pharmaceutical composition for the prevention or treatment of metabolic syndrome comprising a substance having activity toward glucagon receptors or a combination thereof, and a compound or substance having therapeutic activity toward metabolic syndrome, or a combination containing the same.
[0258] Another embodiment of the present invention is a pharmaceutical composition for the prevention or treatment of metabolic syndrome, comprising a substance having activity toward glucagon receptors or a conjugate thereof, characterized by being used in combination with a compound or substance having therapeutic activity toward metabolic syndrome.
[0260] Another embodiment of the present invention is a pharmaceutical kit for the prevention or treatment of metabolic syndrome comprising a substance having activity toward glucagon receptors or a combination thereof and a compound or substance having therapeutic activity toward metabolic syndrome; and a combination or composition comprising the same.
[0262] Another embodiment of the present invention is a method for preventing or treating metabolic syndrome, comprising the step of administering a substance having activity toward glucagon receptors or a conjugate thereof and a compound or substance having therapeutic activity toward metabolic syndrome to an individual in need thereof.
[0264] Another embodiment of the present invention is a composition comprising a peptide having activity toward a glucagon receptor or a conjugate containing the same, specifically a pharmaceutical composition for the prevention or treatment of metabolic syndrome, hypoglycemia, or congenital hyperinsulinism.
[0266] In one embodiment, the metabolic syndrome is characterized by being one or more diseases selected from the group consisting of impaired glucose tolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, nonalcoholic steatohepatitis (NASH), arteriosclerosis due to dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease (coronary heart disease), and stroke.
[0268] In the preceding embodiment, the peptide having activity against glucagon receptors is characterized as being natural glucagon, an agonist thereof, or a derivative thereof.
[0270] The derivative of natural glucagon according to any one of the preceding embodiments is characterized in that one or more amino acids are mutated from natural glucagon, and said mutation is a mutation selected from the group consisting of substitution, addition, deletion, modification, and combinations thereof.
[0271] A pharmaceutical composition according to any one of the preceding embodiments is characterized in that the peptide having activity toward a glucagon receptor is a glucagon derivative peptide comprising the amino acid sequence of General Formula 1 below:
[0273] X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-X24-WL-X27-X28-X29-X30 (General Formula 1, Sequence No.: 45)
[0275] In the above formula,
[0276] X1 is histidine (H), desamino-histidyl, N-dimethyl-histidyl, beta-hydroxy imidazopropionyl, 4-imidazoacetyl, beta-carboxy imidazopropionyl, tryptophan (W), or tyrosine (Y), or is absent;
[0277] X2 is alpha-methyl-glutamic acid, Aib (aminoisobutyric acid), D-alanine, glycine (G), Sar (N-methylglycine), serine (S), or D-serine;
[0278] X7 is threonine (T), valine (V), or cysteine (C);
[0279] X10 is tyrosine (Y) or cysteine (C);
[0280] X12 is lysine (K) or cysteine (C);
[0281] X13 is tyrosine (Y) or cysteine (C);
[0282] X14 is leucine (L) or cysteine (C);
[0283] X15 is aspartic acid (D), glutamic acid (E), or cysteine (C);
[0284] X16 is glutamic acid (E), aspartic acid (D), serine (S), alpha-methylglutamic acid, or cysteine (C), or is absent;
[0285] X17 is aspartic acid (D), glutamine (Q), glutamic acid (E), lysine (K), arginine (R), serine (S), cysteine (C), or valine (V), or is absent;
[0286] X18 is alanine (A), aspartic acid (D), glutamic acid (E), arginine (R), valine (V), or cysteine (C), or is absent;
[0287] X19 is alanine (A), arginine (R), serine (S), valine (V), or cysteine (C), or is absent;
[0288] X20 is lysine (K), histidine (H), glutamine (Q), aspartic acid (D), arginine (R), alpha-methylglutamic acid, or cysteine (C), or is absent;
[0289] X21 is aspartic acid (D), glutamic acid (E), leucine (L), valine (V), or cysteine (C), or is absent;
[0290] X23 is isoleucine (I), valine (V), or arginine (R), or is absent;
[0291] X24 is valine (V), arginine (R), alanine (A), cysteine (C), glutamic acid (E), lysine (K), glutamine (Q), alpha-methylglutamic acid, or leucine (L), or is absent;
[0292] X27 is isoleucine (I), valine (V), alanine (A), lysine (K), methionine (M), glutamine (Q), or arginine (R), or is absent;
[0293] X28 is glutamine (Q), lysine (K), asparagine (N), or arginine (R), or is absent;
[0294] X29 is lysine (K), alanine (A), glycine (G), or threonine (T), or is absent;
[0295] X30 is cysteine (C) or non-existent
[0296] (However, cases where the amino acid sequence of the above General Formula 1 is identical to SEQ ID NO: 1 are excluded).
[0298] In the preceding specific examples,
[0299] In the above general formula 1
[0300] X1 is histidine (H), tryptophan (W), or tyrosine (Y), or is absent;
[0301] X2 is serine (S) or Aib (aminoisobutyric acid);
[0302] X7 is threonine (T), valine (V), or cysteine (C);
[0303] X10 is tyrosine (Y) or cysteine (C);
[0304] X12 is lysine (K) or cysteine (C);
[0305] X13 is tyrosine (Y) or cysteine (C);
[0306] X14 is leucine (L) or cysteine (C);
[0307] X15 is aspartic acid (D) or cysteine (C);
[0308] X16 is glutamic acid (E), serine (S), or cysteine (C);
[0309] X17 is aspartic acid (D), glutamic acid (E), lysine (K), arginine (R), serine (S), cysteine (C), or valine (V);
[0310] X18 is aspartic acid (D), glutamic acid (E), arginine (R), or cysteine (C);
[0311] X19 is alanine (A) or cysteine (C);
[0312] X20 is glutamine (Q), aspartic acid (D), lysine (K), or cysteine (C);
[0313] X21 is aspartic acid (D), glutamic acid (E), leucine (L), valine (V), or cysteine (C);
[0314] X23 is isoleucine (I), valine (V), or arginine (R);
[0315] X24 is valine (V), arginine (R), alanine (A), glutamic acid (E), lysine (K), glutamine (Q), or leucine (L);
[0316] X27 is isoleucine (I), valine (V), alanine (A), methionine (M), glutamine (Q) or arginine (R);
[0317] X28 is glutamine (Q), lysine (K), asparagine (N), or arginine (R);
[0318] X29 is threonine (T);
[0319] X30 is characterized by being cysteine (C) or being absent.
[0321] As a pharmaceutical composition according to any one of the aforementioned embodiments,
[0322] In the above general formula 1
[0323] X1 is histidine (H), tryptophan (W), or tyrosine (Y);
[0324] X2 is serine (S) or Aib (aminoisobutyric acid);
[0325] X7 is cysteine (C), threonine (T), or valine (V);
[0326] X10 is tyrosine (Y) or cysteine (C);
[0327] X12 is lysine (K) or cysteine (C);
[0328] X13 is tyrosine (Y) or cysteine (C);
[0329] X14 is leucine (L) or cysteine (C);
[0330] X15 is aspartic acid (D) or cysteine (C);
[0331] X16 is glutamic acid (E), serine (S), or cysteine (C);
[0332] X17 is glutamic acid (E), lysine (K), arginine (R), cysteine (C), or valine (V);
[0333] X18 is arginine (R) or cysteine (C);
[0334] X19 is alanine (A) or cysteine (C);
[0335] X20 is glutamine (Q) or lysine (K);
[0336] X21 is aspartic acid (D), glutamic acid (E), valine (V), or cysteine (C);
[0337] X23 is valine (V);
[0338] X24 is valine (V) or glutamine (Q);
[0339] X27 is methionine (M);
[0340] X28 is asparagine (N) or arginine (R);
[0341] X29 is threonine (T);
[0342] X30 is characterized by being cysteine (C) or being absent.
[0344] As a pharmaceutical composition according to any one of the aforementioned embodiments,
[0345] In the above general formula 1
[0346] X1 is tyrosine (Y);
[0347] X2 is Aib (aminoisobutyric acid);
[0348] X7 is cysteine (C), threonine (T), or valine (V);
[0349] X10 is tyrosine (Y) or cysteine (C);
[0350] X12 is Lee Sin (K);
[0351] X13 is tyrosine (Y) or cysteine (C);
[0352] X14 is leucine (L) or cysteine (C);
[0353] X15 is aspartic acid (D) or cysteine (C);
[0354] X16 is glutamic acid (E), serine (S), or cysteine (C);
[0355] X17 is lysine (K), arginine (R), cysteine (C), or valine (V);
[0356] X18 is arginine (R) or cysteine (C);
[0357] X19 is alanine (A) or cysteine (C);
[0358] X20 is glutamine (Q) or lysine (K);
[0359] X21 is aspartic acid (D), glutamic acid (E), or cysteine (C);
[0360] X23 is valine (V);
[0361] X24 is glutamine (Q);
[0362] X27 is methionine (M);
[0363] X28 is asparagine (N) or arginine (R);
[0364] X29 is threonine (T);
[0365] X30 is characterized by being cysteine (C) or being absent.
[0367] As a pharmaceutical composition according to any one of the aforementioned embodiments,
[0368] In the above general formula 1
[0369] X1 is histidine (H), tryptophan (W), or tyrosine (Y), or is absent;
[0370] X2 is serine (S) or Aib (aminoisobutyric acid);
[0371] X7 is threonine (T), valine (V), or cysteine (C);
[0372] X10 is tyrosine (Y) or cysteine (C);
[0373] X12 is lysine (K) or cysteine (C);
[0374] X13 is tyrosine (Y) or cysteine (C);
[0375] X14 is leucine (L) or cysteine (C);
[0376] X15 is aspartic acid (D) or cysteine (C);
[0377] X16 is glutamic acid (E), serine (S), or cysteine (C);
[0378] X17 is aspartic acid (D), glutamic acid (E), lysine (K), arginine (R), serine (S), cysteine (C), or valine (V);
[0379] X18 is aspartic acid (D), glutamic acid (E), arginine (R), or cysteine (C);
[0380] X19 is alanine (A) or cysteine (C);
[0381] X20 is glutamine (Q), aspartic acid (D), or lysine (K);
[0382] X21 is aspartic acid (D) or glutamic acid (E);
[0383] X23 is valine (V);
[0384] X24 is valine (V) or glutamine (Q);
[0385] X27 is isoleucine (I) or methionine (M);
[0386] X28 is asparagine (N) or arginine (R);
[0387] X29 is threonine (T);
[0388] X30 is characterized by being cysteine (C) or being absent.
[0390] As a pharmaceutical composition according to any one of the aforementioned embodiments,
[0391] In the above general formula 1
[0392] X1 is tyrosine (Y);
[0393] X2 is Aib (aminoisobutyric acid);
[0394] X7 is threonine (T);
[0395] X10 is tyrosine (Y);
[0396] X12 is Lee Sin (K);
[0397] X13 is tyrosine (Y);
[0398] X14 is leucine (L);
[0399] X15 is aspartic acid (D) or cysteine (C);
[0400] X16 is glutamic acid (E), serine (S), or cysteine (C);
[0401] X17 is lysine (K) or arginine (R);
[0402] X18 is arginine(R);
[0403] X19 is alanine (A);
[0404] X20 is glutamine (Q), cysteine (C), or lysine (K);
[0405] X21 is aspartic acid (D), cysteine (C), valine (V), or glutamic acid (E);
[0406] X23 is valine (V) or arginine (R);
[0407] X24 is glutamine (Q) or leucine (L);
[0408] X27 is methionine (M);
[0409] X28 is asparagine (N) or arginine (R);
[0410] X29 is threonine (T);
[0411] X30 is characterized by non-existence.
[0413] A pharmaceutical composition according to any one of the preceding embodiments, wherein the peptide is characterized as being a peptide comprising the amino acid sequence of the following general formula 2:
[0415] Y-Aib-QGTF-X7-SD-X10-S-X12-YL-X15-X16-X17-RA-X20-X21-FV-X24-WLMNT-X30 (General Formula 2, Sequence No.: 46)
[0417] In the above general formula 2
[0418] X7 is threonine (T), valine (V), or cysteine (C);
[0419] X10 is tyrosine (Y) or cysteine (C);
[0420] X12 is lysine (K) or cysteine (C);
[0421] X15 is aspartic acid (D) or cysteine (C);
[0422] X16 is glutamic acid (E) or serine (S);
[0423] X17 is lysine (K) or arginine (R);
[0424] X20 is glutamine (Q) or lysine (K);
[0425] X21 is aspartic acid (D) or glutamic acid (E);
[0426] X24 is valine (V) or glutamine (Q);
[0427] X30 is cysteine (C) or is absent.
[0430] A pharmaceutical composition according to any one of the preceding embodiments, wherein the peptide is characterized by having a pI different from that of natural glucagon, which is 6.8, such as a pI of 6.5 or less or a pI of 7.0 or more.
[0432] As a pharmaceutical composition according to any one of the preceding embodiments, one specific form of the present invention is characterized in that each of the amino acids of at least one amino acid pair among the amino acid pairs of X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20 and X24, and X24 and X28 of the general formula 1 or 2 is substituted with glutamic acid or lysine capable of forming a ring.
[0434] As a pharmaceutical composition according to any one of the preceding embodiments, one specific form of the present invention is characterized in that each of the amino acids of the X12 and X16 amino acid pair, the X16 and X20 amino acid pair, or the X17 and X21 amino acid pair of the above general formula 1 or 2 is substituted with glutamic acid or lysine capable of forming a ring.
[0436] As a pharmaceutical composition according to any one of the preceding embodiments, one specific form of the present invention is characterized by forming a ring (e.g., a lactam ring) between each amino acid in at least one amino acid pair among the amino acid pairs of X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20 and X24, and X24 and X28 in the above general formula 1 or 2.
[0438] A pharmaceutical composition according to any one of the preceding embodiments, wherein one specific form of the present invention is characterized in that, in the above general formula 1 or 2, X16 is glutamic acid and X20 is lysine, and the side chains of X16 and X20 form a lactam ring.
[0440] As a pharmaceutical composition according to any one of the preceding embodiments, one specific form of the present invention is characterized in that the C-terminus of the peptide is amidated or not modified.
[0442] A pharmaceutical composition according to any one of the aforementioned embodiments is characterized in that the peptide is a derivative of natural glucagon capable of activating glucagon receptors.
[0444] A pharmaceutical composition according to any one of the preceding embodiments, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 2 to 44.
[0446] A pharmaceutical composition according to any one of the preceding embodiments is characterized in that the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 13, 15 and 36 to 44.
[0448] A pharmaceutical composition according to any one of the preceding embodiments, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 37.
[0450] A pharmaceutical composition according to any one of the aforementioned embodiments is characterized in that the peptide is in the form of a sustained conjugate, wherein a biocompatible material portion is bound to the peptide portion, specifically a peptide portion comprising an amino acid sequence of General Formula 1 or 2.
[0452] A pharmaceutical composition according to any one of the aforementioned embodiments, wherein the biocompatible material part is selected from the group consisting of a polymer, a fatty acid, cholesterol, albumin and fragments thereof, an albumin binding material, a polymer of repeating units of a specific amino acid sequence, an antibody, an antibody fragment, an FcRn binding material, an in vivo connective tissue or a derivative thereof, a nucleotide, a fibronectin, a transferrin, a saccharide, a heparin, and an elastin.
[0454] A pharmaceutical composition according to any one of the preceding embodiments is characterized in that the polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.
[0456] A pharmaceutical composition according to any one of the aforementioned embodiments is characterized in that the FcRn binding material is a polypeptide comprising an immunoglobulin Fc region.
[0458] A pharmaceutical composition according to any one of the aforementioned embodiments is characterized in that the peptide portion and the biocompatible material portion are connected to each other through a linker.
[0460] A pharmaceutical composition according to any one of the aforementioned embodiments is characterized in that the linker is selected from the group consisting of peptides, fatty acids, sugars, high molecular weight polymers, low molecular weight compounds, nucleotides, and combinations thereof.
[0462] A pharmaceutical composition according to any one of the preceding embodiments is characterized in that the polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.
[0464] A pharmaceutical composition according to any one of the preceding embodiments, wherein the linker is polyethylene glycol.
[0466] A pharmaceutical composition according to any one of the aforementioned embodiments, wherein the immunoglobulin Fc region is characterized by being non-glycosylated.
[0468] As a pharmaceutical composition according to any one of the aforementioned embodiments, the immunoglobulin Fc region is
[0469] (a) CH1 domain, CH2 domain, CH3 domain and CH4 domain;
[0470] (b) CH1 domain and CH2 domain;
[0471] (c) CH1 domain and CH3 domain;
[0472] (d) CH2 domain and CH3 domain;
[0473] (e) a combination of one or more of the CH1 domain, CH2 domain, CH3 domain and CH4 domain with an immunoglobulin hinge region or a part of the hinge region; and
[0474] (f) Dimer of each domain of the heavy chain invariant region and the light chain invariant region
[0475] It is characterized by being selected from a group composed of
[0477] A pharmaceutical composition according to any one of the aforementioned embodiments is characterized in that the polypeptide containing the immunoglobulin Fc region is in a dimeric form.
[0479] A pharmaceutical composition according to any one of the aforementioned embodiments is characterized in that the immunoglobulin Fc region is a derivative of natural Fc in which a site capable of forming disulfide bonds is removed, some amino acids at the N-terminus of natural Fc are removed, a methionine residue is added to the N-terminus of natural Fc, a complement binding site is removed, or an ADCC (antibody dependent cell mediated cytotoxicity) site is removed.
[0481] A pharmaceutical composition according to any one of the aforementioned embodiments is characterized in that the immunoglobulin Fc region is an Fc region derived from an immunoglobulin selected from the group consisting of IgG, IgA, IgD, IgE, and IgM.
[0483] A pharmaceutical composition according to any one of the aforementioned embodiments is characterized in that the immunoglobulin Fc region is an IgG4 Fc region.
[0485] A pharmaceutical composition according to any one of the aforementioned embodiments is characterized in that the immunoglobulin Fc region is a non-glycosylated Fc region derived from human IgG4.
[0487] A pharmaceutical composition according to any one of the aforementioned embodiments, wherein the linker is connected to a cysteine residue of a peptide having activity for the glucagon receptor, or a peptide comprising the amino acid sequence of General Formula 1 or 2.
[0489] As a pharmaceutical composition according to any one of the preceding embodiments, and as a specific form of the present invention, the linker of the conjugate is characterized in that one end is connected to an amine group or a thiol group of the biocompatible material part and the other end of the linker is connected to the peptide part and the biocompatible material part by a covalent bond formed by reacting with the amine group or a thiol group of the peptide part having activity for the glucagon receptor, or the amino acid sequence of General Formula 1 or 2, respectively.
[0491] Another embodiment of the present invention is a pharmaceutical composition for the prevention or treatment of hypoglycemia comprising a peptide having activity toward a glucagon receptor or a conjugate containing the same; and a pharmaceutically acceptable excipient.
[0493] In one embodiment, the present invention relates to a pharmaceutical composition for the prevention or treatment of hypoglycemia, comprising: a peptide having activity toward the glucagon receptor; or a separated conjugate comprising a peptide portion having the same sequence as or including the same as the peptide and a biocompatible material portion covalently connected to the peptide portion.
[0495] Another embodiment of the present invention is a pharmaceutical composition for the prevention or treatment of congenital hyperinsulinism comprising: a peptide having activity toward a glucagon receptor or a conjugate containing the same; and a pharmaceutically acceptable excipient.
[0497] In one embodiment, the present invention relates to a pharmaceutical composition for the prevention or treatment of congenital hyperinsulinism, comprising: a peptide having activity for the glucagon receptor; or a separated conjugate comprising a peptide region having the same sequence as or including the same as the peptide having activity for the glucagon receptor, and a biocompatible material portion covalently connected to the peptide region.
[0499] Another embodiment of the present invention is a pharmaceutical composition for the prevention or treatment of obesity comprising a peptide having activity toward a glucagon receptor or a conjugate containing the same; and a pharmaceutically acceptable excipient.
[0501] In one embodiment, the present invention relates to a pharmaceutical composition for the prevention or treatment of obesity, comprising: a peptide having activity for the glucagon receptor; or a separated conjugate comprising a peptide portion having the same sequence as or including the same as the peptide having activity for the glucagon receptor, and a biocompatible material portion covalently connected to the peptide portion.
[0503] Another embodiment of the present invention is a pharmaceutical composition for the prevention or treatment of metabolic syndrome comprising a peptide having activity toward a glucagon receptor or a conjugate containing the same; and a pharmaceutically acceptable excipient.
[0505] In one embodiment, the invention relates to a pharmaceutical composition for the prevention or treatment of metabolic syndrome, comprising: a peptide having activity for the glucagon receptor; or a separated conjugate comprising a peptide region having the same sequence as or including the same as the peptide having activity for the glucagon receptor, and a biocompatible material portion covalently connected to the peptide region. Effects of the invention
[0507] The administration of a peptide having activity toward glucagon receptors according to the present invention; or the combined administration of a substance having activity toward glucagon receptors and a compound or substance having therapeutic activity toward metabolic syndrome may be useful for the prevention or treatment of obesity, diabetes, metabolic syndrome including nonalcoholic steatohepatitis (NASH), congenital hyperinsulinism, and / or hypoglycemia. Brief explanation of the drawing
[0509] Figure 1 shows the results of measuring the change in body weight over 4 weeks of drug administration compared to before administration. Figure 2 (A) is a graph showing the change in mesenteric fat mass after 4 weeks of drug administration. Figure 2 (B) is a graph showing the change in HOMA-IR, an indicator of insulin sensitivity improvement, after 4 weeks of drug administration. Figure 3 shows the results of measuring changes in blood glucose levels over 4 weeks of drug administration. Figure 4 shows the results of measuring the change in body weight over 4 weeks of drug administration compared to before administration. Figure 5 (A) is a graph showing the change in mesenteric fat mass after 4 weeks of drug administration. Figure 5 (B) is a graph showing the change in HOMA-IR, an indicator of insulin sensitivity improvement, after 4 weeks of drug administration. Figure 6 shows the results of measuring changes in blood glucose levels over 4 weeks of drug administration. Figure 7 shows the results confirming the weight loss effect following drug administration. Figures 8(A) and (B) show the results confirming fat reduction and improvement in blood lipid levels. Figure 9 shows the results of measuring changes in blood glucose. Specific details for implementing the invention
[0510] The specific details for implementing the present invention are described as follows. Meanwhile, each description and embodiment disclosed herein may be applied to other descriptions and embodiments. That is, all combinations of the various elements disclosed herein fall within the scope of the present invention. Furthermore, the scope of the present invention is not to be limited by the specific descriptions provided below.
[0511] In addition, a person skilled in the art can recognize or identify a number of equivalents to the specific embodiments of the invention described in this application using only ordinary experiments. In addition, such equivalents are intended to be included in the invention.
[0512] Throughout this specification, not only are the usual one-letter and three-letter codes for naturally occurring amino acids used, but also the generally accepted three-letter codes for other amino acids such as Aib (α-aminoisobutyric acid), Sar (N-methylglycine), etc., are used. Additionally, amino acids referred to by abbreviations in this specification are described according to the IUPAC-IUB nomenclature.
[0514] Alanine A Arginine R
[0515] Asparagine N Aspartic acid D
[0516] Cysteine C, Glutamic Acid E
[0517] Glutamine Q Glycine G
[0518] Histidine H, Isoleucine I
[0519] Leucin L Lee Sin K
[0520] Methionine M Phenylalanine F
[0521] Proline P Serine S
[0522] Threonine T Tryptophan W
[0523] Tyrosine Y Valine V
[0525] One embodiment of the present invention provides a therapeutic use of a substance or a conjugate thereof having activity toward glucagon receptors and a compound or substance having therapeutic activity toward metabolic syndrome.
[0527] Specifically, one aspect of the present invention provides a combination, pharmaceutical composition, or kit comprising a substance having activity toward a glucagon receptor or a conjugate thereof and a compound or substance having therapeutic activity toward metabolic syndrome. In one embodiment, a combination, pharmaceutical composition, or kit for the prevention or treatment of metabolic syndrome is provided.
[0529] In the present invention, the term “combination” refers to the use of a substance or a combination thereof having activity toward glucagon receptors and a compound or substance having therapeutic activity toward metabolic syndrome administered in combination, and can be understood as having the same meaning as “combined used.” The said combination
[0530] a) administered as a mixture comprising (i) a substance having activity toward glucagon receptors or a conjugate thereof and (ii) a compound or substance having therapeutic activity toward metabolic syndrome; or
[0531] b) (i) a substance or a conjugate thereof having activity toward glucagon receptors and (ii) a compound or substance having therapeutic activity toward metabolic syndrome may be administered in separate forms, but are not limited thereto.
[0532] When a substance or conjugate thereof having activity on glucagon receptors and a compound or substance having therapeutic activity for metabolic syndrome are in separate forms, the substance or conjugate thereof having activity on glucagon receptors and the compound or substance having therapeutic activity for metabolic syndrome may be formulated into separate preparations and administered simultaneously, individually, sequentially, or in reverse order.
[0533] In the present invention, concomitant administration should be understood not merely as simultaneous administration, but as a form of administration in which a substance or conjugate thereof having activity toward glucagon receptors and a compound or substance having therapeutic activity toward metabolic syndrome act together on an individual so that each substance can perform a level equivalent to or greater than its inherent function. Accordingly, when the term "concomitant" is used herein, it should be understood to indicate simultaneous, individual, sequential, or reverse administration. Where said administration is sequential, reverse, or individual, the order of administration is not particularly limited, provided that the interval between the administration of the secondary component is such that the beneficial effects of said concomitant administration are not lost.
[0535] In the present invention, the term “composition comprising a combination” may be the combination itself comprising a substance having activity toward the glucagon receptor or a combination thereof and a compound or substance having therapeutic activity toward metabolic syndrome, or may include such a combination and have a therapeutic use, but is not limited thereto. For example, it may have a use for the prevention or treatment of metabolic syndrome, but is not limited thereto. In this invention, “composition comprising a combination” may be used interchangeably with “composition.”
[0536] A composition comprising a combination according to the present invention is intended for co-administering a substance having activity toward glucagon receptors or a conjugate thereof and a compound or substance having therapeutic activity toward metabolic syndrome, wherein the substance having activity toward glucagon receptors or a conjugate thereof and the compound or substance having therapeutic activity toward metabolic syndrome may be formulated into a single preparation or may be formulated individually. Specifically, the substance having activity toward glucagon receptors or a conjugate thereof and the compound or substance having therapeutic activity toward metabolic syndrome may be administered simultaneously, individually, sequentially, or in reverse order, but are not limited thereto.
[0538] In the present invention, the term “kit” may include a combination or composition according to the present invention for co-administering a substance or conjugate thereof having activity toward glucagon receptors and a compound or substance having therapeutic activity toward metabolic syndrome. Specifically, the kit according to the present invention may include a substance or conjugate thereof having activity toward glucagon receptors and a compound or substance having therapeutic activity toward metabolic syndrome formulated into a single preparation, or individual preparations of a substance or conjugate thereof having activity toward glucagon receptors and a compound or substance having therapeutic activity toward metabolic syndrome, and may additionally include a substance necessary for co-administration of the two substances, but is not limited thereto.
[0540] The substance having activity against the glucagon receptor includes various substances having a significant level of activity against the glucagon receptor, such as compounds or substances in the form of peptides.
[0541] Although not specifically limited thereto, substances having a significant level of activity against the above-mentioned glucagon include not only natural glucagon but also glucagon receptors in vitroThe activity may be greater than 0.1%, greater than 1%, greater than 2%, greater than 3%, greater than 4%, greater than 5%, greater than 6%, greater than 7%, greater than 8%, greater than 9%, greater than 10%, greater than 20%, greater than 30%, greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 100% compared to the natural ligand (natural glucagon) of the corresponding receptor.
[0543] Examples of substances having activity against the above-mentioned glucagon receptor include natural glucagon, agonists thereof, or derivatives thereof, but may be specifically limited thereto.
[0545] The glucagon derivative according to the present invention comprises a peptide having one or more differences in amino acid sequences compared to natural glucagon, a peptide modified through modification of the natural glucagon sequence, or a mimic of natural glucagon capable of activating glucagon receptors like natural glucagon. For example, the derivative of natural glucagon is one in which one or more amino acids have been mutated from natural glucagon, and said mutation may be a mutation selected from the group consisting of substitution, addition, deletion, modification, and combinations thereof, but is not particularly limited thereto.
[0547] These glucagon derivatives may have a modified pI compared to natural glucagon and exhibit improved physical properties. Additionally, the glucagon derivatives may have improved solubility while possessing activity that activates glucagon receptors, but are not limited thereto.
[0548] In addition, the above glucagon derivative may be non-naturally occurring.
[0550] Meanwhile, natural glucagon can have the following amino acid sequence:
[0551] His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr(Sequence No.: 1)
[0553] In the present invention, the term “isoelectric point” or “pI” refers to a pH value at which a polypeptide or molecule such as a peptide has no total net charge (0). In the case of a polypeptide having various charged functional groups, the sum of these charges at pI is zero. At a pH higher than pI, the total net charge of the polypeptide will be negative, and at a pH lower than pI, the total net charge of the polypeptide will be positive.
[0554] pI can be determined by isoelectric point electrophoresis on a fixed pH gradient gel composed of polyacrylamide, starch, or agarose, or by estimating pI from an amino acid sequence using, for example, the pI / MW tool (http: / / expasy.org / tools / pi_tool.html; Gasteiger et al., 2003) on an ExPASy server.
[0555] In the present invention, the term "modified pI" means that some sequences in the amino acid sequence of natural glucagon are substituted with negatively and positively charged amino acid residues, resulting in a pI different from that of natural glucagon, that is, a pI that is reduced or increased. Peptides having such a modified pI may exhibit improved solubility and / or high stability at neutral pH as glucagon derivatives. However, they are not particularly limited thereto.
[0556] More specifically, the glucagon derivative may have a modified pI value other than the pI value (6.8) of natural glucagon, more specifically a pI value less than 6.8, specifically 6.7 or less, more specifically 6.5 or less, and more specifically greater than 6.8, 7 or more, more specifically 7.5 or more, but is not limited thereto, and is included in the scope of the present invention if it has a pI value different from that of natural glucagon. In particular, it is particularly included in the scope of the present invention if it has a pI value different from that of natural glucagon and exhibits improved solubility at a neutral pH compared to natural glucagon, thereby having a low degree of aggregation.
[0557] More specifically, it may have a pI value of 4 to 6.5 and / or 7 to 9.5, more specifically 7.5 to 9.5, and even more specifically 8.0 to 9.3, but is not limited thereto. In this case, because it has a higher or lower pI than natural glucagon, it may exhibit improved solubility and high stability compared to natural glucagon at neutral pH. However, it is not limited thereto.
[0559] Specifically, derivatives of natural glucagon can be modified by substituting, adding, deleting, and modifying some amino acids in natural glucagon, or by a combination of these methods.
[0560] Examples of glucagon derivatives prepared by a combination of these methods include, but are not limited to, peptides having an activating function for glucagon receptors that differ from natural glucagon in one or more amino acid sequences and have deamination of the N-terminal amino acid residue, and derivatives of natural glucagon applicable to the present invention can be prepared by a combination of various methods for preparing derivatives.
[0561] In addition, such modifications for the preparation of derivatives of natural glucagon include modifications using L- or D-type amino acids and / or non-natural amino acids; and / or modifications by modifying the natural sequence, e.g., modification of side chain functional groups, intramolecular covalent bonds, e.g., inter-side chain ring formation, methylation, acylation, ubiquitination, phosphorylation, aminohexalation, biotinylation, etc. In addition, the modifications include all substitutions with non-natural compounds.
[0562] In addition, it includes all of the addition of one or more amino acids to the amino and / or carboxyl terminals of natural glucagon.
[0563] The aforementioned substituted or added amino acids may include the 20 amino acids typically observed in human proteins, as well as atypical or non-naturally occurring amino acids. Commercial sources of atypical amino acids include Sigma-Aldrich, ChemPep, and Genzyme Pharmaceuticals. Peptides containing these amino acids and typical peptide sequences can be synthesized and purchased through commercial peptide synthesis companies, for example, American Peptide Company or Bachem in the United States, or Anygen in Korea.
[0564] Amino acid derivatives can also be obtained in the same way, and to give just a few examples, 4-imidazoacetic acid can be used.
[0566] Glucagon has a pI of approximately 7, making it insoluble in solutions with a physiological pH (pH 4-8) and prone to precipitation at neutral pH. In aqueous solutions with a pH of 3 or lower, glucagon initially dissolves but precipitates within one hour due to gel formation. Gelled glucagon consists primarily of β-sheet fibrils, and this precipitated glucagon is unsuitable for use as an injectable because the gel can clog blood vessels if administered via a needle or intravenously. To delay the precipitation process, acidic formulations (pH 2-4) are typically used, which allows glucagon to remain in a relatively non-aggregated state for a short period. However, because glucagon fibril formation occurs very rapidly at low pH, these acidic formulations must be injected immediately after preparation.
[0568] The glucagon derivative of the present invention includes one developed to have an extended action profile by changing the pI of natural glucagon by substituting negatively and positively charged amino acid residues, and is characterized by having a changed pI compared to natural glucagon, thereby exhibiting improved solubility and / or high stability at neutral pH.
[0570] As one specific embodiment, the glucagon derivative may be a peptide comprising the amino acid sequence of the following general formula 1.
[0572] X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-X24-WL-X27-X28-X29-X30 (General Formula 1, Sequence No.: 45)
[0574] In the above formula,
[0575] X1 is histidine, desamino-histidyl, N-dimethyl-histidyl, beta-hydroxy imidazopropionyl, 4-imidazoacetyl, beta-carboxy imidazopropionyl, tryptophan, or tyrosine, or is absent;
[0576] X2 is alpha-methyl-glutamic acid, Aib (aminoisobutyric acid), D-alanine, glycine, Sar (N-methylglycine), serine, or D-serine;
[0577] X7 is threonine, valine, or cysteine;
[0578] X10 is tyrosine or cysteine;
[0579] X12 is lysine or cysteine;
[0580] X13 is tyrosine or cysteine;
[0581] X14 is leucine or cysteine;
[0582] X15 is aspartic acid, glutamic acid, or cysteine;
[0583] X16 is glutamic acid, aspartic acid, serine, alpha-methylglutamic acid, or cysteine, or is absent;
[0584] X17 is aspartic acid, glutamine, glutamic acid, lysine, arginine, serine, cysteine, or valine, or is absent;
[0585] X18 is alanine, aspartic acid, glutamic acid, arginine, valine, or cysteine, or is absent;
[0586] X19 is alanine, arginine, serine, valine, or cysteine, or is absent;
[0587] X20 is lysine, histidine, glutamine, aspartic acid, arginine, alpha-methylglutamic acid, or cysteine, or is absent;
[0588] X21 is aspartic acid, glutamic acid, leucine, valine, or cysteine, or is absent;
[0589] X23 is isoleucine, valine, or arginine, or is absent;
[0590] X24 is valine, arginine, alanine, cysteine, glutamic acid, lysine, glutamine, alpha-methylglutamic acid, or leucine, or is absent;
[0591] X27 is isoleucine, valine, alanine, lysine, methionine, glutamine, or arginine, or is absent;
[0592] X28 is glutamine, lysine, asparagine, or arginine, or is absent;
[0593] X29 is lysine, alanine, glycine, or threonine, or is absent;
[0594] X30 is cysteine or may be absent.
[0595] (However, cases where the amino acid sequence of the above General Formula 1 is identical to SEQ ID NO: 1 are excluded).
[0597] More specifically,
[0598] In the above general formula 1,
[0599] X1 is histidine, tryptophan, or tyrosine, or is absent;
[0600] X2 is serine or Aib (aminoisobutyric acid);
[0601] X7 is threonine, valine, or cysteine;
[0602] X10 is tyrosine or cysteine;
[0603] X12 is lysine or cysteine;
[0604] X13 is tyrosine or cysteine;
[0605] X14 is leucine or cysteine;
[0606] X15 is aspartic acid, or cysteine;
[0607] X16 is glutamic acid, serine, or cysteine;
[0608] X17 is aspartic acid, glutamic acid, lysine, arginine, serine, cysteine, or valine;
[0609] X18 is aspartic acid, glutamic acid, arginine, or cysteine;
[0610] X19 is alanine, or cysteine;
[0611] X20 is glutamine, aspartic acid, lysine, or cysteine;
[0612] X21 is aspartic acid, glutamic acid, leucine, valine, or cysteine;
[0613] X23 is isoleucine, valine, or arginine;
[0614] X24 is valine, arginine, alanine, glutamic acid, lysine, glutamine, or leucine;
[0615] X27 is isoleucine, valine, alanine, methionine, glutamine, or arginine;
[0616] X28 is glutamine, lysine, asparagine, or arginine;
[0617] X29 is threonine;
[0618] X30 may be cysteine or be absent (except where the amino acid sequence of General Formula 1 is identical to that of Sequence No. 1).
[0620] For example, the above peptide may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 44, specifically (essentially) composed of an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 44, but is not limited thereto.
[0621] In addition, even if the present invention is described as "a peptide consisting of a specific sequence number," if it has the same or corresponding activity as a peptide consisting of the amino acid sequence of the said sequence number, it does not exclude meaningless sequence additions before or after the amino acid sequence of the said sequence number, naturally occurring mutations, or silent mutations thereof, and it is obvious that even in cases having such sequence additions or mutations, it falls within the scope of the present invention.
[0622] The above description may be applied to other embodiments or aspects of the present invention, but is not limited thereto.
[0624] Specifically, in the above general formula 1,
[0625] In the above general formula 1
[0626] X1 is histidine, tryptophan, or tyrosine;
[0627] X2 is serine or Aib (aminoisobutyric acid);
[0628] X7 is cysteine, threonine, or valine;
[0629] X10 is tyrosine or cysteine;
[0630] X12 is lysine or cysteine;
[0631] X13 is tyrosine or cysteine;
[0632] X14 is leucine or cysteine;
[0633] X15 is aspartic acid, or cysteine;
[0634] X16 is glutamic acid, serine, or cysteine;
[0635] X17 is glutamic acid, lysine, arginine, cysteine, or valine;
[0636] X18 is arginine, or cysteine;
[0637] X19 is alanine, or cysteine;
[0638] X20 is glutamine or lysine;
[0639] X21 is aspartic acid, glutamic acid, valine, or cysteine;
[0640] X23 is valine;
[0641] X24 is valine or glutamine;
[0642] X27 is methionine;
[0643] X28 is asparagine or arginine;
[0644] X29 is threonine;
[0645] X30 may be cysteine or may be non-existent.
[0647] For example, the above peptide may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 11 to 17, 19 to 27, 29, 31, 33, 35 to 44, specifically (essentially) composed of an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 11 to 17, 19 to 27, 29, 31, 33, 35 to 44, but is not limited thereto.
[0649] Specifically,
[0650] In the above general formula 1
[0651] X1 is tyrosine;
[0652] X2 is Aib (aminoisobutyric acid);
[0653] X7 is cysteine, threonine, or valine;
[0654] X10 is tyrosine or cysteine;
[0655] X12 is Lee Sin;
[0656] X13 is tyrosine or cysteine;
[0657] X14 is leucine or cysteine;
[0658] X15 is aspartic acid, or cysteine;
[0659] X16 is glutamic acid, serine, or cysteine;
[0660] X17 is lysine, arginine, cysteine, or valine;
[0661] X18 is arginine, or cysteine;
[0662] X19 is alanine, or cysteine;
[0663] X20 is glutamine or lysine;
[0664] X21 is aspartic acid, glutamic acid, or cysteine;
[0665] X23 is valine;
[0666] X24 is glutamine;
[0667] X27 is methionine;
[0668] X28 is asparagine or arginine;
[0669] X29 is threonine;
[0670] X30 may be cysteine or be absent (except where the amino acid sequence of General Formula 1 is identical to SEQ ID NO: 1).
[0672] For example, the above peptide may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 14, 17, 19 to 25, 27, 29, 33, 35 to 38, 40 to 42, and 44, specifically (essentially) composed of an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 14, 17, 19 to 25, 27, 29, 33, 35 to 38, and 40 to 42, and 44, but is not limited thereto.
[0674] Specifically, in the above general formula 1
[0675] X1 is histidine, tryptophan, or tyrosine, or is absent;
[0676] X2 is serine or Aib (aminoisobutyric acid);
[0677] X7 is threonine, valine, or cysteine;
[0678] X10 is tyrosine or cysteine;
[0679] X12 is lysine or cysteine;
[0680] X13 is tyrosine or cysteine;
[0681] X14 is leucine or cysteine;
[0682] X15 is aspartic acid, or cysteine;
[0683] X16 is glutamic acid, serine, or cysteine;
[0684] X17 is aspartic acid, glutamic acid, lysine, arginine, serine, cysteine, or valine;
[0685] X18 is aspartic acid, glutamic acid, arginine, or cysteine;
[0686] X19 is alanine, or cysteine;
[0687] X20 is glutamine, aspartic acid, or lysine;
[0688] X21 is aspartic acid or glutamic acid;
[0689] X23 is valine;
[0690] X24 is valine or glutamine;
[0691] X27 is isoleucine or methionine;
[0692] X28 is asparagine or arginine;
[0693] X29 is threonine;
[0694] X30 may be cysteine or be absent (except where the amino acid sequence of General Formula 1 is identical to that of Sequence No. 1).
[0696] For example, the above peptide may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs 2 to 13, 15, 17, 20 to 24, 26 to 30, and 32 to 44, specifically (essentially) composed of an amino acid sequence selected from the group consisting of SEQ ID NOs 2 to 13, 15, 17, 20 to 24, 26 to 30, and 32 to 44, but is not limited thereto.
[0698] Specifically, in the above general formula 1
[0699] X1 is tyrosine or;
[0700] X2 is Aib (aminoisobutyric acid);
[0701] X7 is threonine;
[0702] X10 is tyrosine;
[0703] X12 is Lee Sin;
[0704] X13 is tyrosine;
[0705] X14 is leucine;
[0706] X15 is aspartic acid, or cysteine;
[0707] X16 is glutamic acid, serine, or cysteine;
[0708] X17 is lysine or arginine;
[0709] X18 is arginine;
[0710] X19 is alanine;
[0711] X20 is glutamine, cysteine, or lysine;
[0712] X21 is aspartic acid, cysteine, valine, or glutamic acid;
[0713] X23 is valine or arginine;
[0714] X24 is glutamine or leucine;
[0715] X27 is methionine;
[0716] X28 is asparagine or arginine;
[0717] X29 is threonine;
[0718] X30 may not exist.
[0720] For example, the above peptide may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 16, 18, 19, 25, and 31, specifically (essentially) composed of an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 16, 18, 19, 25, and 31, but is not limited thereto.
[0722] More specifically, the peptide may be a peptide comprising the amino acid sequence of the following general formula 2:
[0724] Y-Aib-QGTF-X7-SD-X10-S-X12-YL-X15-X16-X17-RA-X20-X21-FV-X24-WLMNT-X30 (General Formula 2, Sequence No.: 46)
[0726] In the above general formula 2
[0727] X7 is threonine, valine, or cysteine;
[0728] X10 is tyrosine or cysteine;
[0729] X12 is lysine or cysteine;
[0730] X15 is aspartic acid, or cysteine;
[0731] X16 is glutamic acid or serine;
[0732] X17 is lysine or arginine;
[0733] X20 is glutamine or lysine;
[0734] X21 is aspartic acid or glutamic acid;
[0735] X24 is valine or glutamine;
[0736] X30 is cysteine or may be absent.
[0738] For example, the above peptide may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 13, 15, and 36 to 44, specifically (essentially) composed of an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 13, 15, and 36 to 44, but is not limited thereto. More specifically, the above peptide is characterized by comprising the amino acid sequence of SEQ ID NO: 12, 20, or 37, or being (essentially) composed of said amino acid sequence. However, it is not limited thereto.
[0740] Specifically, in the above general formula 2
[0741] X7 is threonine, valine, or cysteine;
[0742] X10 is tyrosine or cysteine;
[0743] X12 is Lee Sin;
[0744] X15 is aspartic acid;
[0745] X16 is glutamic acid or serine;
[0746] X17 is lysine or arginine;
[0747] X20 is glutamine or lysine;
[0748] X21 is aspartic acid or glutamic acid;
[0749] X24 is glutamine;
[0750] X30 may be cysteine or be absent, but is not specifically limited to this.
[0751] For example, the above peptide may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 36 to 38, 40 to 42, and 44, specifically (essentially) composed of an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 36 to 38, 40 to 42, and 44, but is not limited thereto.
[0752] However, among the separated peptides above, there may be combinations of peptides corresponding to SEQ ID NOs: 2 to 11, 14, 16 to 35, 49, and 50, specifically SEQ ID NOs: 19, 33, 49, and 50 that are excluded from the claimed category, but are not particularly limited thereto, and unless otherwise stated in the claim, all peptides described in the claim are included in the scope of the present invention.
[0754] The glucagon derivative described above may include an intramolecular bridge (e.g., a covalent or non-covalent bridge), and specifically, may be in a form including a ring. For example, it may be in a form in which a ring is formed between amino acids 16 and 20 of the glucagon derivative, but is not particularly limited thereto.
[0755] Non-limiting examples of the above ring may include a lactam crosslink (or lactam ring).
[0756] In addition, the above glucagon derivatives include all modified ones that include a ring and an amino acid capable of forming a ring at a desired location.
[0757] Such rings may be formed between amino acid side chains within the glucagon derivative, for example, in the form of a lactam ring formed between the side chain of lysine and the side chain of glutamic acid, but are not particularly limited thereto.
[0758] For example, a peptide comprising the amino acid sequence of General Formula 1 or General Formula 2 may be one in which, in the amino acid pairs of X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20 and X24, and X24 and X28 of General Formula 1 or General Formula 2, the amino acid of each amino acid pair is substituted with glutamic acid or lysine, but is not limited thereto. In the above, Xn (n is a natural number), n represents the amino acid position from the N-terminus of the presented amino acid sequence.
[0759] In addition, the peptide containing the amino acid sequence of the above general formula 1 or general formula 2 may have each of the amino acids of the amino acid pair of X12 and X16, the amino acid pair of X16 and X20, or the amino acid pair of X17 and X21 substituted with glutamic acid or lysine capable of forming a ring, but is not limited thereto.
[0760] In addition, in the above general formula 1 or 2, a ring (e.g., a lactam ring) may be formed between each amino acid of each amino acid of at least one amino acid pair among X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20 and X24, and X24 and X28, but is not limited thereto.
[0761] In addition, in the above general formula 1 or 2, X16 is glutamic acid and X20 is lysine, and the side chains of X16 and X20 may form a lactam ring, but are not limited thereto.
[0763] In addition, the peptide according to the present invention may have an unmodified N-terminus and / or C-terminus, but forms in which the N-terminus and / or C-terminus, etc. are chemically modified, protected by an organic group, or modified by adding an amino acid to the peptide terminus, etc., in order to protect against protein-cleaving enzymes in vivo and increase stability, are also included in the scope of the peptide according to the present invention. In the case where the C-terminus is unmodified, the terminus of the peptide according to the present invention has a carboxyl group, but is not particularly limited thereto.
[0764] In particular, in the case of chemically synthesized peptides, since the N- and C-terminals are charged, the N-terminal may be acetylated and / or the C-terminal may be amidated to remove these charges, but is not specifically limited thereto.
[0765] Unless otherwise indicated in this specification, the description in the detailed specification or claims regarding the “peptide” or “conjugate” in which such peptide is covalently linked to a biocompatible material according to the present invention applies to the category including not only said peptide or conjugate, but also said salt of said peptide or conjugate (e.g., a pharmaceutically acceptable salt of said peptide), or a solvate thereof. Accordingly, even if the specification only refers to “peptide” or “conjugate,” such description applies likewise to said specific salt, said specific solvate, and said specific solvate of said specific salt. Such salt forms may be, for example, any pharmaceutically acceptable salt. The type of said salt is not particularly limited. However, it is preferable that it be a form that is safe and effective for individuals, e.g., mammals, but is not particularly limited thereto.
[0766] The above term, "pharmaceuticalally acceptable," means a substance that can be effectively used for a desired purpose without causing excessive toxicity, irritation, or allergic reactions, within the scope of pharmaceutical judgment.
[0767] In the present invention, the term “pharmaceutically acceptable salt” includes a salt derived from a pharmaceutically acceptable inorganic acid, organic acid, or base. Examples of suitable acids include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, etc. Salts derived from suitable bases may include alkali metals such as sodium and potassium, alkaline earth metals such as magnesium, and ammonium, etc.
[0768] In addition, the term "solvent" used in the present invention refers to a peptide, conjugate, or salt thereof according to the present invention forming a complex with a solvent molecule.
[0770] In addition, the glucagon derivative peptide of the present invention can be synthesized by methods well known in the field, for example, by an automated peptide synthesizer, depending on its length, and can also be produced by genetic engineering technology.
[0771] Specifically, the glucagon derivative peptide of the present invention may be prepared by standard synthesis methods, recombinant expression systems, or any other method in the art. Accordingly, the glucagon derivative according to the present invention may be synthesized by a number of methods, including, for example, methods comprising the following:
[0772] (a) a method for synthesizing a peptide stepwise or by fragment assembly by means of a solid-phase or liquid-phase method, and isolating and purifying the final peptide product; or
[0773] (b) a method of expressing a nucleic acid construct encoding a peptide in a host cell and recovering the expression product from a host cell culture; or
[0774] (c) a method for performing cell-free in vitro expression of a nucleic acid construct encoding a peptide and recovering the expression product; or
[0775] A method for obtaining a peptide fragment by any combination of (a), (b) and (c), then linking the fragments to obtain a peptide, and recovering the peptide.
[0776] As a more specific example, a fusion gene encoding a fusion protein containing a fusion partner and a glucagon derivative can be produced through genetic engineering, transformed into a host cell, expressed in the form of a fusion protein, and the glucagon derivative can be cleaved and separated from the fusion protein using a protease or a compound to produce the desired glucagon derivative. To this end, a DNA sequence encoding an amino acid residue that can be cleaved by, for example, a protease such as Factor Xa or enterokinase, or a compound such as CNBr or hydroxylamine, can be inserted between the polynucleotides encoding the fusion partner and the glucagon derivative.
[0778] In a more specific embodiment, a substance having activity toward a glucagon receptor (e.g., a glucagon derivative, e.g., a peptide comprising the amino acid sequence of General Formula 1 or 2) may be in the form of a sustained conjugate bound to a biocompatible material portion that increases its in vivo half-life, but is not limited thereto. The biocompatible material portion may be mixed with a carrier.
[0779] Specifically, the substance having activity toward the glucagon receptor in the above conjugate may be in the form of a peptide, and may be in a form in which a biocompatible material part is attached to a peptide portion having activity toward the glucagon receptor, but is not particularly limited thereto.
[0780] More specifically, the conjugate comprises a peptide portion and a biocompatible material portion covalently connected to the peptide portion, wherein the peptide portion may be a sequence identical to the amino acid sequence of General Formula 1 or 2 or a sequence including the same.
[0781] In the present invention, the term "sustained-release conjugate" refers to a conjugate in which a biocompatible material part or a carrier is bound to a physiologically active substance (e.g., a substance having activity toward a glucagon receptor, an insulin secretion peptide, etc.), and which exhibits sustained efficacy (e.g., increased half-life in the body) compared to a physiologically active substance to which the biocompatible material part or carrier is not bound. In the sustained-release conjugate, the biocompatible material part or the carrier may be connected to the physiologically active substance by a covalent bond, but is not particularly limited thereto.
[0782] In a specific embodiment of the present invention, the conjugate of the glucagon derivative may have increased duration of efficacy compared to natural glucagon or glucagon derivatives without a carrier bond.
[0783] In the present invention, the term "biocompatible material part" refers to a substance that is bound to a physiologically active substance (e.g., a substance having activity toward a glucagon receptor, an insulin secretion peptide, etc.) and can increase the duration of the efficacy of the physiologically active substance compared to a physiologically active substance that is not bound to the biocompatible material part or a carrier. The biocompatible material part may be connected to the physiologically active substance by a covalent bond, but is not particularly limited thereto.
[0784] Examples of the above-mentioned biocompatible material part include, but are not limited to, polymers, fatty acids, cholesterol, albumin and fragments thereof, albumin binding materials, polymers of repeating units of specific amino acid sequences, antibodies, antibody fragments, FcRn binding materials, in vivo connective tissue or derivatives thereof, nucleotides, fibronectin, transferrin, sugars, heparin, or elastin.
[0785] Examples of the above polymers include, but are not limited to, polymers selected from the group consisting of polyethylene glycol (PEG), polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof.
[0786] The above polyethylene glycol is a term that encompasses all forms of ethylene glycol homopolymers, PEG copolymers, or monomethyl-substituted PEG polymers (mPEG), but is not specifically limited thereto.
[0787] In addition, the biocompatible material part includes poly-amino acids such as poly-lysine, poly-aspartic acid, and poly-glutamic acid, but is not limited thereto.
[0788] In addition, fatty acids may have binding affinity with albumin in vivo, but are not specifically limited thereto.
[0789] As a more specific example, the above FcRn binding substance may be an immunoglobulin Fc region, and more specifically, an IgG Fc region, but is not particularly limited thereto.
[0790] One or more amino acid side chains within the material of the present invention having activity toward glucagon receptors may be conjugated to the biocompatible material portion to increase solubility and / or half-life in vivo and / or increase bioavailability. Such modification may also reduce the clearance of therapeutic proteins and peptides.
[0791] These biocompatible material parts may be water-soluble (amphiphilic or hydrophilic) and / or non-toxic and / or pharmaceutically acceptable.
[0792] It is a well known fact to those skilled in the art that such modified glucagon derivatives can exhibit superior therapeutic effects compared to natural glucagon. Therefore, variants of the glucagon derivatives described above are also included within the scope of the glucagon derivatives of the present invention.
[0794] The above biocompatible material part may be directly connected to a substance having activity for the glucagon receptor or connected through a linker. When the above biocompatible material part is directly connected to a substance having activity for the glucagon receptor or connected through a linker, it may be connected by a covalent bond.
[0795] Specifically, the linker may be a peptide linker or a non-peptide linker.
[0796] When the above linker is a peptide linker, it may contain one or more amino acids, for example, from one to 1,000 amino acids, but is not particularly limited thereto. Various known peptide linkers may be used in the present invention, examples including [GS]x linkers, [GGGS]x linkers, and [GGGGGS]x linkers, etc., where x may be a natural number greater than or equal to 1. However, it is not limited to the above examples.
[0797] In the present invention, the "non-peptide linker" comprises a biocompatible polymer in which two or more repeating units are combined. The repeating units are connected to each other through any covalent bond other than a peptide bond. The non-peptide linker may be a component forming a moiety of the complex of the present invention.
[0798] In the present invention, the non-peptide linker can be used in combination with a non-peptide polymer.
[0799] In one specific embodiment, the biocompatible material part (specifically, an immunoglobulin Fc region) and the peptide may be covalently connected through a non-peptide linker comprising a reactive group that can be combined with the peptide drug at each end, respectively.
[0800] Specifically, the non-peptide linker may be selected from the group consisting of fatty acids, saccharides, high molecular weight polymers, low molecular weight compounds, nucleotides, and combinations thereof.
[0801] Although not specifically limited thereto, the polymer in the present invention may be in the range of greater than 0 to about 100 kDa, specifically in the range of about 1 to about 100 kDa, more specifically in the range of about 1 to about 20 kDa, but is not limited thereto.
[0802] Although not specifically limited thereto, the above-mentioned non-peptide linker may be selected from the group consisting of polyethylene glycol, polypropylene glycol, copolymers of ethylene glycol and propylene glycol, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides, dextran, polyvinylethyl ether, biodegradable polymers such as PLA (polylactic acid) and PLGA (polylactic-glycolic acid); lipid polymers; chitins; hyaluronic acid; oligonucleotides and combinations thereof.
[0803] In a more specific embodiment, the non-peptide polymer may be polyethylene glycol, but is not limited thereto. Furthermore, derivatives thereof already known in the art and derivatives that can be easily prepared at the technical level of the art are also included within the scope of the present invention.
[0804] The nonpeptide linker that can be used in the present invention may be used without limitation as long as it is a polymer resistant to in vivo proteolytic enzymes. The molecular weight of the nonpeptide polymer is in the range of greater than 0 and less than or equal to about 100 kDa, specifically in the range of about 1 to 100 kDa, specifically in the range of about 1 to about 20 kDa, but is not limited thereto. In addition, the nonpeptide linker of the present invention that is combined with the polypeptide containing the immunoglobulin Fc region may be a combination of different types of polymers as well as a single type of polymer.
[0805] In the present invention, the term "approximately" includes a range encompassing ±0.5, ±0.4, ±0.3, ±0.2, ±0.1, etc., and includes all numerical values within a range equivalent to or similar to the numerical value following the term "approximately," but is not limited thereto.
[0806] Specifically, the linker may be connected to the peptide portion and the biocompatible material portion by a covalent bond formed by reacting one end with an amine group or a thiol group of the biocompatible material portion and the other end of the linker with a peptide portion, specifically an amine group or a thiol group of the amino acid sequence of General Formula 1 or 2.
[0807] In one specific embodiment, one end of the nonpeptide linker may react with an amine group or a thiol group of the immunoglobulin Fc region, and the other end of the linker may react with an amine group or a thiol group of the glucagon derivative to form a covalent bond. Specifically, the nonpeptide polymer may include, but is not limited to, a reactive group at each end that can be combined with a biocompatible material part, specifically an immunoglobulin Fc region and a glucagon derivative, such as an amine group located at the N-terminus or lysine of the glucagon derivative, or a thiol group of cysteine, or a reactive group that can form a covalent bond between the biocompatible material and the glucagon derivative by reacting with an amine group located at the N-terminus or lysine of the biocompatible material (e.g., specifically, an immunoglobulin Fc region), or a thiol group of cysteine.
[0808] In addition, the terminal reactive group of the nonpeptide polymer, which can be combined with a biocompatible material part, specifically an immunoglobulin Fc region and a glucagon derivative, may be selected from the group consisting of aldehyde groups, maleimide groups and succinimide derivatives, but is not limited thereto.
[0809] In the above, propionaldehyde or butylaldehyde groups may be given as examples of aldehyde groups, but are not limited thereto.
[0810] In the above, succinimidyl valerate, succinimidyl methylbutanoate, succinimidyl methylpropionate, succinimidyl butanoate, succinimidyl propionate, N-hydroxysuccinimidyl, hydroxysuccinimidyl, succinimidyl carboxymethyl or succinimidyl carbonate may be used as succinimidyl derivatives, but are not limited thereto.
[0811] In addition, the final product produced by reductive amination via aldehyde bonds is much more stable than that linked by amide bonds. The aldehyde reactive group selectively reacts at the N-terminus at low pH and can form covalent bonds with lysine residues at high pH, for example, pH 9.0.
[0812] Additionally, the reactive groups at both ends may be identical or different from each other; for example, one end may have a maleimide group and the other end may have an aldehyde group, a propionaldehyde group, or a butylaldehyde group. However, it is not particularly limited to cases where an immunoglobulin Fc region and a glucagon derivative can be attached to each end of the non-peptide linker.
[0813] For example, one end of the above-mentioned nonpeptide linker may include a maleimide group as a reactive group, and the other end may include an aldehyde group, a propionaldehyde group, or a butylaldehyde group, etc.
[0814] When polyethylene glycol having hydroxyl reactive groups at both ends is used as a non-peptide polymer, the hydroxyl groups can be activated into the various reactive groups by known chemical reactions, or the sustained-release protein conjugate of the present invention can be prepared using commercially available polyethylene glycol having modified reactive groups.
[0815] In one specific embodiment, the non-peptide polymer may be connected to a cysteine residue of a glucagon derivative, more specifically to the -SH group of cysteine, but is not limited thereto. Here, the non-peptide polymer may be polyethylene glycol, but is not particularly limited thereto, and other types of non-peptide polymers described above may also be applicable.
[0816] In a specific embodiment, the conjugate comprises a peptide having the amino acid sequence of SEQ ID NO: 12, 20, or 37 and an immunoglobulin Fc region connected via a non-peptide polymer, wherein the non-peptide polymer may be connected to a cysteine residue at position 30 in the amino acid sequence of SEQ ID NO: 12, a cysteine residue at position 17 in the amino acid sequence of SEQ ID NO: 20, or a cysteine residue at position 30 in the amino acid sequence of SEQ ID NO: 37. However, it is not limited thereto. Here, the non-peptide polymer may be polyethylene glycol, but is not particularly limited thereto, and other types of non-peptide polymers described above may also be applicable.
[0817] If maleimide-PEG-aldehyde is used, the maleimide group may be connected to the -SH group of the glucagon derivative via a thioether bond, and the aldehyde group may be connected to the -NH2 group of immunoglobulin Fc via a reductive amination reaction, but is not limited thereto, and this is just one example.
[0818] Additionally, in the above conjugate, the reactive group of the non-peptide polymer may be connected to the -NH2 located at the N-terminus of the immunoglobulin Fc region, but this is just one example.
[0820] In the present invention, "immunoglobulin Fc region" refers to a region comprising a heavy chain constant region 2 (CH2) and / or a heavy chain constant region 3 (CH3), excluding the heavy chain and light chain variable regions of the immunoglobulin. The immunoglobulin Fc region may be a component forming a moiety of the protein conjugate of the present invention.
[0822] Such immunoglobulin Fc regions may include a hinge portion in the heavy chain constant region, but are not limited thereto. Additionally, the immunoglobulin Fc region of the present invention may be an extended Fc region comprising some or all of the heavy chain constant region 1 (CH1) and / or light chain constant region 1 (CL1), excluding only the heavy chain and light chain variable regions of the immunoglobulin, provided that it has substantially equivalent or enhanced effects to the natural form. Additionally, it may be a region in which a significantly long partial amino acid sequence corresponding to CH2 and / or CH3 has been removed.
[0823] For example, the immunoglobulin Fc region of the present invention may be 1) a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain, 2) a CH1 domain and a CH2 domain, 3) a CH1 domain and a CH3 domain, 4) a CH2 domain and a CH3 domain, 5) a combination of one or more domains among the CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain and an immunoglobulin hinge region (or a part of a hinge region), and 6) a dimer of each domain of the heavy chain constant region and the light chain constant region. However, it is not limited thereto.
[0824] Additionally, as one specific example, the immunoglobulin Fc region may be in a dimeric form, and one molecule of a glucagon derivative may be covalently connected to one Fc region in the dimeric form, wherein the immunoglobulin Fc and the glucagon derivative may be connected to each other by a non-peptide polymer. Meanwhile, it is also possible for two molecules of a glucagon derivative to be symmetrically connected to one Fc region in the dimeric form. In this case, the immunoglobulin Fc and the glucagon derivative may be connected to each other by a non-peptide linker. However, the above examples are not limited to those described above.
[0825] In addition, the immunoglobulin Fc region of the present invention includes not only natural amino acid sequences but also sequence derivatives thereof. An amino acid sequence derivative means having a different sequence in which one or more amino acid residues of the natural amino acid sequence are deleted, inserted, non-conservative or conservatively substituted, or a combination thereof.
[0826] For example, in the case of IgG Fc, amino acid residues 214 to 238, 297 to 299, 318 to 322, or 327 to 331, which are known to be important for binding, can be used as suitable sites for modification.
[0827] In addition, various types of derivatives are possible, such as by removing a site capable of forming disulfide bonds, removing some amino acids from the N-terminus of the natural form Fc, or adding a methionine residue to the N-terminus of the natural form Fc. Furthermore, to eliminate effector function, complement binding sites, such as the C1q binding site, may be removed, or the ADCC (antibody dependent cell mediated cytotoxicity) site may be removed. Techniques for manufacturing sequence derivatives of such immunoglobulin Fc regions are disclosed in International Patent Publication No. WO 97 / 34631, International Patent Publication No. 96 / 32478, etc.
[0828] Amino acid exchanges in proteins and peptides that do not alter the overall activity of the molecule are known in the art (H. Neuras, RLHill, The Proteins, Academic Press, New York, 1979). The most common exchanges are between amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, and Asp / Gly. In some cases, modifications may be made through phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, acetylation, and amidation.
[0829] The Fc derivative described above may exhibit biological activity equivalent to the Fc region of the present invention and may have increased structural stability of the Fc region against heat, pH, etc.
[0831] In addition, this Fc region may be obtained from a natural form isolated in vivo from animals such as humans, cattle, goats, pigs, mice, rabbits, hamsters, rats, or guinea pigs, or it may be a recombinant form obtained from transformed animal cells or microorganisms, or a derivative thereof. Here, the method of obtaining from the natural form may be a method of obtaining the total immunoglobulin by isolating it from the body of a human or animal and then treating it with a protease. When treated with papain, it is cleaved into Fab and Fc, and when treated with pepsin, it is cleaved into pF'c and F(ab)2. Fc or pF'c can be separated using size-exclusion chromatography, etc. In a more specific embodiment, the human-derived Fc region is a recombinant immunoglobulin Fc region obtained from microorganisms.
[0832] Furthermore, the immunoglobulin Fc region may be in the form of a natural glycosylation, an increased glycosylation compared to the natural form, a decreased glycosylation compared to the natural form, or a form with the glycosylation removed. Conventional methods, such as chemical methods, enzymatic methods, and genetic engineering methods using microorganisms, can be utilized for increasing, decreasing, or removing these immunoglobulin Fc glycosylations. Here, the immunoglobulin Fc region with the glycosylation removed exhibits significantly reduced binding affinity to complement (c1q), and since antibody-dependent cytotoxicity or complement-dependent cytotoxicity is reduced or eliminated, it does not induce unnecessary immune responses in vivo. In this regard, the form with the glycosylation removed or deglycosylated immunoglobulin Fc region is considered to be more suitable for its original purpose as a drug carrier.
[0833] In the present invention, "deglycosylation" refers to the Fc region from which sugar has been removed by an enzyme, and "aglycosylation" refers to the Fc region that has not been glycosylated, produced in prokaryotes, or in a more specific embodiment, in E. coli.
[0834] Meanwhile, the immunoglobulin Fc region may be of human or animal origin such as cattle, goats, pigs, mice, rabbits, hamsters, rats, guinea pigs, etc., and in a more specific embodiment, it is of human origin.
[0835] Additionally, the immunoglobulin Fc region may be an Fc region derived from IgG, IgA, IgD, IgE, or IgM, or a combination or hybrid thereof. In a more specific embodiment, it is derived from IgG or IgM, which are most abundant in human blood, and in an even more specific embodiment, it is derived from IgG, which is known to enhance the half-life of ligand-binding proteins. In a more specific embodiment, the immunoglobulin Fc region is an IgG4 Fc region, and in the most specific embodiment, the immunoglobulin Fc region is a non-glycosylated Fc region derived from human IgG4, but is not limited thereto.
[0837] Meanwhile, in the present invention, "combination" means that when forming a dimer or a multimer, a polypeptide encoding a short-chain immunoglobulin Fc region of the same origin forms a combination with a short-chain polypeptide of a different origin. That is, it is possible to prepare a dimer or a multimer from two or more fragments selected from the group consisting of IgG Fc, IgA Fc, IgM Fc, IgD Fc, and IgE Fc fragments.
[0839] The composition, combination, or kit of the present invention may be used for the prevention or treatment of metabolic syndrome.
[0840] In the present invention, the term "prevention" refers to any act of suppressing or delaying the onset of a target disease, such as metabolic syndrome, by administering a substance having glucagon activity or a combination thereof, a compound or substance having therapeutic activity against metabolic syndrome, or a combination or composition containing the same, and "treatment" refers to any act of improving or benefiting the symptoms of a target disease, such as metabolic syndrome, by administering a substance having glucagon activity or a combination thereof, a compound or substance having therapeutic activity against metabolic syndrome, or a combination or composition containing the same.
[0841] In the present invention, the term "administration" means introducing a specific substance to a patient by any appropriate method. The route of administration of the composition is not specifically limited thereto, but may be administered through any general route capable of reaching a target in vivo, such as intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, local administration, nasal administration, pulmonary administration, rectal administration, etc.
[0842] The above-mentioned glucagon derivative or conjugate containing it may be used for the prevention or treatment of metabolic syndrome, either alone or in combination with a compound or substance having therapeutic activity against metabolic syndrome.
[0843] In addition, the glucagon-active substance or conjugate thereof of the present invention may be used as a drug to prevent weight gain, promote weight loss, reduce excess weight, or treat obesity including morbid obesity (e.g., by controlling appetite, eating, food intake, calorie intake and / or energy expenditure), as well as related diseases and health conditions including, but not limited to, obesity-related inflammation, obesity-related gallbladder disease, and obesity-induced sleep apnea. The glucagon-active substance or conjugate thereof of the present invention may also be used to treat metabolic syndrome other than obesity, namely, impaired glucose tolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, nonalcoholic steatohepatitis (NASH), arteriosclerosis caused by dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease, and stroke. However, in these pathological conditions, the effect of the peptide according to the present invention may be mediated wholly or partially through the aforementioned body weight-related effect, or it may be independent thereof.
[0845] In the present invention, the term "metabolic syndrome" refers to a condition in which various diseases resulting from chronic metabolic disorders occur individually or in combination. In particular, diseases corresponding to metabolic syndrome include, but are not limited to, impaired glucose tolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, nonalcoholic steatohepatitis (NASH), arteriosclerosis due to dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease (coronary artery heart disease), and stroke.
[0846] In the present invention, the term "obesity" refers to a condition in which there is an excessive amount of adipose tissue in the body, and is defined as obesity if the body obesity index (a value obtained by dividing body weight (kg) by the square of height (m)) is 25 or higher. Obesity is typically caused by an energy imbalance resulting from the excessive intake of nutrients compared to energy consumption over a long period. Obesity is a metabolic disease that affects the entire body, increasing the likelihood of developing diabetes and hyperlipidemia, raising the risk of sexual dysfunction, arthritis, and cardiovascular disease, and in some cases, is also associated with the development of cancer.
[0847] The glucagon derivative according to the present invention has a modified pI compared to natural glucagon, which can exhibit improved solubility and high stability at neutral pH, and can also exhibit activity against glucagon receptors, so it can be usefully used for the prevention or treatment of target diseases including metabolic syndrome.
[0849] The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient, or diluent. In the present invention, the term "pharmaceutically acceptable" means a sufficient amount to produce a therapeutic effect and not causing side effects, and can be readily determined by a person skilled in the art based on factors well known in the medical field, such as the type of disease, the patient's age, weight, health, gender, the patient's sensitivity to drugs, route of administration, method of administration, frequency of administration, duration of treatment, and drugs used in combination or concurrently.
[0850] The pharmaceutical composition of the present invention, comprising a substance having glucagon activity or a conjugate thereof, may further comprise a pharmaceutically acceptable carrier. The carrier is not particularly limited thereto, but for oral administration, a binder, lubricant, disintegrant, excipient, solubilizer, dispersant, stabilizer, suspending agent, colorant, flavoring agent, etc. may be used; for injectable formulations, a buffer, preservative, analgesic, solubilizer, isotonic agent, stabilizer, etc. may be mixed and used; and for topical administration, a base, excipient, lubricant, preservative, etc. may be used.
[0851] The formulations of the composition of the present invention can be prepared in various ways by mixing with pharmaceutically acceptable carriers as described above. For example, for oral administration, it can be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and for injectables, it can be prepared in the form of unit dosing ampoules or multi-dose formulations. In addition, it can be formulated into solutions, suspensions, tablets, pills, capsules, sustained-release formulations, etc.
[0852] Meanwhile, examples of carriers, excipients, and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil. Additionally, fillers, anticoagulants, lubricants, wetting agents, fragrances, preservatives, etc. may be additionally included.
[0853] In addition, the pharmaceutical composition of the present invention may have any one formulation selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid formulations, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, lyophilized formulations, and suppositories.
[0855] In addition, the above composition may be formulated into a unit dosage form suitable for administration into a patient's body according to conventional methods in the pharmaceutical field, specifically in a form useful for administering peptide drugs, and administered orally or by a parenteral administration route including the skin, intravenously, intramuscularly, intra-arterially, intramedullaryly, intrathecally, intraventricularly, pulmonaryly, transdermally, subcutaneously, intraabdominally, intranasally, gastrointestinally, topically, sublingually, vaginally, or rectal route using administration methods conventionally used in the industry, but is not limited thereto.
[0856] In addition, the substance having glucagon activity or a conjugate thereof may be used in combination with various carriers permitted as pharmaceuticals, such as physiological saline or organic solvents, and to increase stability or absorption, carbohydrates such as glucose, sucrose, or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, or other stabilizers may be used as pharmaceuticals.
[0857] The dosage and frequency of administration of the pharmaceutical composition of the present invention are determined according to the type of active ingredient drug, along with various relevant factors such as the disease to be treated, the route of administration, the patient's age, gender, weight, and the severity of the disease.
[0858] Although not specifically limited thereto, the pharmaceutical composition of the present invention may contain the above component (active ingredient) in an amount of 0.01 to 99% by weight to volume.
[0860] The total effective amount of the composition of the present invention may be administered to a patient as a single dose, or administered via a fractionated treatment protocol involving multiple doses over a long period. The content of the active ingredient in the pharmaceutical composition of the present invention may vary depending on the severity of the disease. Specifically, the preferred total dose of the glucagon derivative peptide or conjugate of the present invention may be about 0.0001 μg to 500 mg per day per 1 kg of the patient's body weight. However, since the effective dose for the patient is determined by considering various factors such as the patient's age, weight, health status, gender, severity of the disease, diet, and excretion rate, as well as the route of administration and frequency of treatment of the pharmaceutical composition, a person of ordinary knowledge in the art will be able to determine an appropriate effective dose for a specific use of the composition of the present invention in light of these factors. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, route of administration, and method of administration as long as it exhibits the effects of the present invention.
[0861] The pharmaceutical composition of the present invention may have excellent in vivo persistence and potency and may exhibit a lower number and frequency of administration compared to other drugs, but is not particularly limited thereto.
[0862] In particular, since the pharmaceutical composition of the present invention contains a glucagon derivative having a modified pI compared to natural glucagon as an active ingredient, it exhibits improved solubility and / or high stability at neutral pH, so it can be usefully used to manufacture a stable glucagon formulation for the treatment of a target disease, including metabolic syndrome.
[0864] In the above pharmaceutical composition for the prevention or treatment of metabolic syndrome, or the therapy for the prevention or treatment of metabolic syndrome, in addition to a substance having activity for glucagon receptors or a conjugate thereof, a compound or substance having therapeutic activity for metabolic syndrome may be included, and the therapy may include the additional use of said compound or substance.
[0865] Examples of compounds or substances having therapeutic activity for metabolic syndrome included in the combination administration or composition of the present invention include insulin secretion peptides, GLP-1 (glucagon-like peptide-1) receptor agonists, leptin receptor agonists, DPP-IV (dipeptidyl peptidase-IV) inhibitors, Y5 receptor antagonists, MCH (Melanin-concentrating hormone) receptor antagonists, Y2 / 4 receptor agonists, MC3 / 4 (Melanocortin 3 / 4) receptor agonists, gastric / pancreatic lipase inhibitors, 5HT2c (5-hydroxytryptamine receptor 2C) agonists, G protein-coupled agonists, β3A receptor agonists, Amylin receptor agonists, Ghrelin antagonists, and Ghrelin receptors. Antagonist, PPARα (Peroxisome proliferator-activated receptor alpha) agonist, PPARδ (Peroxisome proliferator-activated receptor delta) agonist, FXR (farnesoid X receptor) agonist, acetyl-CoA carboxylase inhibitor, peptide YY, CCK (Cholecystokinin), Xenin, glicentin, obestatin, secretin, nesfatin, insuin, or GIP (glucose-dependent insulinotropic peptide), biguanides, sulfonylureas, meglitinide, thiazolidinedione (TZD),Examples include SGLT2 (sodium-glucose cotransporter) inhibitors and / or α-glucosidase inhibitors; more specifically, they may be, but are not limited to, DPP-4 inhibitors, SGLT2 inhibitors, or GLP-1 (glucagon-like peptide-1) receptor agonists. Additionally, drugs effective for treating obesity and drugs that inhibit liver inflammation and fibrosis may all be included.
[0867] Specifically, in the present invention, the term “GLP-1 receptor agonist” refers to a substance (compound, peptide, amino acid, etc.) capable of acting on a GLP-1 receptor as one of the substances having therapeutic activity for metabolic syndrome, and may be used interchangeably with “GLP-1 analog” herein. The GLP-1 receptor agonist may exhibit in vitro activity toward a GLP-1 receptor of 0.1% or more, 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100% or more relative to the natural ligand (GLP-1) of the receptor.
[0868] The above DPP-4 inhibitor is any one selected from the group consisting of sitagliptin (e.g., Januvia®), vildagliptin, saxagliptin, alogliptin, linagliptin, Trayenta®), anagliptin, teneligliptin, trelagliptin, gemigliptin, omaglipin, evogliptin, and deutoglipin;
[0869] The above SGLT2 inhibitor may be any one selected from the group consisting of empagliflozin (e.g., Jardiance®), dapagliflozin, canagliflozin, remogliflozin, remogliflozin etabonate, sergliflozin, ipragliflozin, topogliflozin, luceogliflozin, and ertugliflozin, but is not limited thereto as long as it is administered in combination with a substance having activity toward glucagon receptors according to the present invention or a conjugate thereof and can exhibit therapeutic activity.
[0871] Another embodiment of the present invention provides a pharmaceutical composition for the prevention or treatment of metabolic syndrome, comprising a substance having activity toward glucagon receptors or a conjugate thereof, characterized by being used in combination with a compound or substance having therapeutic activity toward metabolic syndrome.
[0872] The substance having activity for the glucagon receptor, the conjugate containing the same, the composition containing the same, metabolic syndrome, prevention, treatment, and pharmaceutical composition are as described above.
[0874] Another embodiment of the present invention provides a method for preventing or treating metabolic syndrome, comprising the step of administering (i) a substance having activity toward glucagon receptors or a conjugate thereof and (ii) a compound or substance having therapeutic activity toward metabolic syndrome to an individual in need thereof.
[0875] The substance having activity for the glucagon receptor, the conjugate containing the same, the composition containing the same, metabolic syndrome, prevention, and treatment are as described above.
[0876] In the present invention, the individual is an individual suspected of having metabolic syndrome. The individual suspected of having metabolic syndrome refers to mammals, including humans, rats, and livestock, that have developed or may develop the disease, but any individual that can be treated with the glucagon derivative of the present invention or the composition containing it is included without limitation. Furthermore, the individual can be efficiently treated by administering a pharmaceutical composition containing the glucagon derivative of the present invention to an individual suspected of having metabolic syndrome. Metabolic syndrome is as described above.
[0877] The method of the present invention may include administering a pharmaceutically effective amount of a combination or pharmaceutical composition comprising (i) a substance having activity toward glucagon receptors or a conjugate thereof and (ii) a compound or substance having therapeutic activity toward metabolic syndrome. The method according to the present invention may involve administering (i) a substance having activity toward glucagon receptors or a conjugate thereof and (ii) a compound or substance having therapeutic activity toward metabolic syndrome as a single preparation, or administering individual preparations simultaneously, individually, sequentially, or in reverse order, but is not limited thereto.
[0878] The appropriate total daily dosage may be determined by the treating physician within the scope of proper medical judgment and may be administered in one or several doses. However, for the purposes of the present invention, it is desirable to apply the specific therapeutically effective dosage for a specific patient differently depending on various factors and similar factors well known in the pharmaceutical field, including the type and degree of response to be achieved, the specific composition including whether other preparations are used in some cases, the patient's age, weight, general health condition, gender and diet, time of administration, route of administration and secretion rate of the composition, duration of treatment, and drugs used together or simultaneously with the specific composition.
[0879] Meanwhile, although not specifically limited thereto, the above method for preventing or treating metabolic syndrome may be a combination therapy further comprising administering one or more compounds or substances having therapeutic activity against metabolic syndrome.
[0881] Another embodiment of the present invention provides a composition comprising a peptide having activity toward a glucagon receptor or a conjugate containing the same, specifically a pharmaceutical composition for the prevention or treatment of metabolic syndrome, hypoglycemia, or congenital hyperinsulinism.
[0882] The above metabolic syndrome may be one or more diseases selected from impaired glucose tolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, nonalcoholic steatohepatitis (NASH), arteriosclerosis due to dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease (coronary artery heart disease), and stroke, but is not limited thereto.
[0884] The peptide having activity for the glucagon receptor described above includes a substance in the form of a peptide having a significant level of activity for the glucagon receptor, and is a substance having activity for the glucagon receptor described above.
[0885] The substance having activity for the glucagon receptor, the conjugate containing the same, the composition containing the same, metabolic syndrome, prevention, and treatment are as described above.
[0887] The pharmaceutical composition of the present invention can be used for the prevention or treatment of metabolic syndrome, hypoglycemia, or congenital hyperinsulinism.
[0889] In the present invention, the term "hypoglycemia" refers to a condition in which blood glucose levels are lower than normal. Typically, it refers to a blood glucose level of 50 mg / dl or less, but is not specifically limited thereto. Common causes of hypoglycemia include cases where a person using oral hypoglycemic agents or insulin consumes less food than usual or engages in excessive activity or exercise. In addition, hypoglycemia may also occur due to alcohol consumption, the use of certain blood glucose-lowering drugs, severe physical illness, hormone deficiencies such as adrenal cortical hormones or glucagon, insulin-producing pancreatic tumors, autoimmune diseases against insulin, patients who have undergone gastrectomy, or hereditary carbohydrate metabolism enzyme disorders.
[0890] In the present invention, the hypoglycemia includes both acute hypoglycemia and chronic hypoglycemia.
[0891] Symptoms of hypoglycemia include weakness, tremors, paleness, cold sweats, dizziness, excitement, anxiety, palpitations, hunger, headache, and fatigue. If hypoglycemia persists for a long time, convulsions or seizures may occur, and a state of shock may result, leading to loss of consciousness.
[0892] More specifically, the above hypoglycemia may be caused by persistent hyperinsulinism due to genetic defects. Causes of hyperinsulinism due to genetic defects include mutations in the SUR or Kir6.2 genes on chromosome 11p15.1, mutations in the GK (glucokinase) gene on chromosome 7p15-p13 which increase GK activity, and mutations in the GDH (gluamate dehydrogenase) gene which activate GDH and thereby increase ATP in beta islets.
[0893] Meanwhile, congenital hyperinsulinism is one of the underlying conditions causing severe and persistent hypoglycemia in newborns and children. It can be induced by a temporary increase in insulin secretion or abnormal pancreatic cell function due to genetic mutations in low-birth-weight infants or infants born to diabetic mothers. It is known that glucagon can be used to treat this congenital hyperinsulinism.
[0895] In addition, the peptide having activity for glucagon receptors according to the present invention, or a conjugate containing the same, may be used as a drug to prevent weight gain, promote weight loss, reduce excess weight, or treat obesity including morbid obesity (e.g., by controlling appetite, eating, food intake, calorie intake and / or energy expenditure), as well as related diseases and health conditions including, but not limited to, obesity-related inflammation, obesity-related gallbladder disease, and obesity-induced sleep apnea. The peptide having activity for glucagon receptors according to the present invention, or a conjugate containing the same, may also be used to treat metabolic syndrome other than obesity, namely, impaired glucose tolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, nonalcoholic steatohepatitis (NASH), arteriosclerosis caused by dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease, and stroke. However, in these pathological conditions, the effect of the peptide according to the present invention may be mediated wholly or partially through the aforementioned body weight-related effect, or it may be independent thereof.
[0897] In the present invention, the term "obesity" refers to a condition in which there is an excessive amount of adipose tissue in the body, and is defined as obesity if the body obesity index (a value obtained by dividing body weight (kg) by the square of height (m)) is 25 or higher. Obesity is typically caused by an energy imbalance resulting from the excessive intake of nutrients compared to energy consumption over a long period. Obesity is a metabolic disease that affects the entire body, increasing the likelihood of developing diabetes and hyperlipidemia, raising the risk of sexual dysfunction, arthritis, and cardiovascular disease, and in some cases, is also associated with the development of cancer.
[0899] The peptide alone having activity toward glucagon receptors according to the present invention can also be usefully used for the prevention or treatment of metabolic syndrome, hypoglycemia, or congenital hyperinsulinism. In addition, glucagon derivatives have a modified pI compared to natural glucagon, which can exhibit improved solubility and high stability at neutral pH and also exhibit activity toward glucagon receptors, so they can be usefully used for the prevention or treatment of target diseases including hypoglycemia, obesity, metabolic syndrome, and congenital hyperinsulinism.
[0901] Another embodiment of the present invention provides a peptide having activity toward a glucagon receptor, namely a glucagon derivative.
[0903] The peptide having activity against the glucagon receptor mentioned above is as described above.
[0905] More specifically, the derivative is characterized as being an isolated peptide comprising the amino acid sequence of General Formula 1 represented by SEQ ID NO: 45. All of the previously described contents apply to the description and combination of the isolated peptide comprising the amino acid sequence of General Formula 1.
[0906] The above derivative is characterized as being an isolated peptide comprising the amino acid sequence of the following general formula 2.
[0908] Y-Aib-QGTF-X7-SD-X10-S-X12-YL-X15-X16-X17-RA-X20-X21-FV-X24-WLMNT-X30 (General Formula 2, Sequence No.: 46)
[0910] In the above general formula 2
[0911] X7 is threonine, valine, or cysteine;
[0912] X10 is tyrosine or cysteine;
[0913] X12 is lysine or cysteine;
[0914] X15 is aspartic acid, or cysteine;
[0915] X16 is glutamic acid or serine;
[0916] X17 is lysine or arginine;
[0917] X20 is glutamine or lysine;
[0918] X21 is aspartic acid or glutamic acid;
[0919] X24 is valine or glutamine;
[0920] X30 is cysteine or absent.
[0922] More specifically, the peptide containing the amino acid sequence of the above general formula 2 may be such that X16 of general formula 2 is glutamic acid and X20 is lysine, and the side chains of X16 and X20 form a lactam ring, but are not limited thereto.
[0923] In addition, the C-terminus of the peptide containing the amino acid sequence of General Formula 2 may be amidated or unmodified, but is not limited thereto.
[0924] In addition, the peptide may be a glucagon derivative capable of activating glucagon receptors, but is not limited thereto.
[0925] More specifically, the peptide may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 13, 15 and 36 to 44, but is not limited thereto.
[0927] Another embodiment of the present invention provides an isolated polynucleotide encoding the glucagon derivative, a vector comprising the polynucleotide, and an isolated cell comprising the polynucleotide or the vector.
[0928] The above-mentioned glucagon derivative is as described above.
[0929] Specifically, the derivative may be an isolated peptide comprising the amino acid sequence of General Formula 1 represented by SEQ ID NO: 45. All previously described contents apply to the description and combination of the isolated peptide comprising the amino acid sequence of General Formula 1. Additionally, specifically, the derivative is characterized as being an isolated peptide comprising the amino acid sequence of General Formula 2 represented by SEQ ID NO: 46. All previously described contents apply to the description and combination of the isolated peptide comprising the amino acid sequence of General Formula 2.
[0930] The term "homology" in the present invention is used to indicate the degree of similarity with a wild-type amino acid sequence and a wild-type nucleic acid sequence, and the comparison of homology is performed visually or using a comparison program that is readily available. Commercially available computer programs can calculate the homology between two or more sequences as a percentage (%). Homology (%) can be calculated for adjacent sequences.
[0931] In the present invention, the term “recombinant vector” means a DNA product in which a target peptide, such as a glucagon derivative, is operably linked to a suitable regulatory sequence so as to be able to express a target peptide, such as a glucagon derivative, within a suitable host.
[0932] The regulatory sequence comprises a promoter capable of initiating transcription, any operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence regulating the termination of transcription and translation. After being transformed into a suitable host cell, the recombinant vector may replicate or function independently of the host genome and may be incorporated into the genome itself.
[0933] The recombinant vector used in the present invention is not particularly limited as long as it is capable of replicating within a host cell, and can be constructed using any vector known in the art. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in their natural or recombinant state. The vectors available for use in the present invention are not particularly limited, and known expression vectors may be used.
[0934] The above recombinant vector is used to transform host cells to produce the glucagon derivative of the present invention. In addition, these transformed cells, which are part of the present invention, may be cultured cells or cell lines used for the proliferation of the nucleic acid fragment and vector of the present invention, or for the recombinant production of the glucagon derivative of the present invention.
[0935] In the present invention, the term "transformation" means introducing a recombinant vector containing a polynucleotide encoding a target protein into a host cell so that the protein encoded by said polynucleotide can be expressed within the host cell. As long as the transformed polynucleotide can be expressed within the host cell, it includes all cases regardless of whether it is inserted into or located outside the chromosomes of the host cell.
[0936] Additionally, the polynucleotide comprises DNA and RNA encoding a target protein. The polynucleotide can be introduced into a host cell and expressed in any form, provided that it can be introduced into the host cell. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a gene structure containing all the elements necessary for self-expression. The expression cassette may typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal operably linked to the polynucleotide. The expression cassette may be in the form of a self-replicating expression vector. Furthermore, the polynucleotide may be introduced into the host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not limited thereto.
[0937] In addition, the term "operably connected" above means that the gene sequence is functionally connected to the promoter sequence that initiates and mediates the transcription of the polynucleotide encoding the peptide of the present invention.
[0938] The host suitable for the present invention is not particularly limited as long as it expresses the polynucleotide of the present invention. Specific examples of hosts that can be used for the present invention include Escherichia coli ( E. coli Escherikia (like ) Escherichia Bacteria of the genus ); Bacillus subtilis( Bacillus subtilis Bacillus such as ) Bacillus ) bacteria; Pseudomonas putida ( Pseudomonas putida Pseudomonas such as ) Pseudomonas ) bacteria; Pychia pastoris( Pichia pastoris ), Saccharomyces cerevisiae( Saccharomyces cerevisiae ), Schizocaromyces pombe ( Schizosaccharomyces pombeThere are yeasts such as ); insect cells such as Spodorophyta prugiferda (Sf9); and animal cells such as CHO, COS, BSC, etc.
[0940] Another embodiment of the present invention provides a separated conjugate comprising a peptide having activity toward a glucagon receptor and a biocompatible material portion that increases the in vivo half-life thereof. The conjugate may be a sustained-release conjugate.
[0941] Specifically, the present invention provides a separated conjugate comprising a peptide portion and a biocompatible material portion covalently connected to the peptide portion, wherein the peptide portion is a sequence identical to the amino acid sequence of General Formula 1 or 2 or a sequence including the same.
[0942] All of the previously described provisions apply to the above-mentioned glucagon derivative, the amino acid sequence of General Formula 1 or 2, the biocompatible material portion, and the composition of the conjugate.
[0943] Specifically, the derivative may be an isolated peptide comprising the amino acid sequence of General Formula 1 represented by SEQ ID NO: 45. All of the previously described details apply to the description and combination of the isolated peptide comprising the amino acid sequence of General Formula 1.
[0944] In addition, specifically, the derivative is characterized as being an isolated peptide comprising the amino acid sequence of General Formula 2 represented by SEQ ID NO: 46. All of the previously described contents apply to the description and combination of the isolated peptide comprising the amino acid sequence of General Formula 2.
[0946] Another embodiment of the present invention provides a method for preventing or treating congenital hyperinsulinism, hypoglycemia, obesity, or metabolic syndrome, comprising the step of administering to an individual a peptide having activity for the glucagon receptor, a conjugate containing the same, or a composition containing the same.
[0947] The peptide having activity for the glucagon receptor, the conjugate containing the same, the composition containing the same, and the prevention and treatment of congenital hyperinsulinism, hypoglycemia, obesity, metabolic syndrome are as described above.
[0948] In the present invention, the subject refers to an individual suspected of having congenital hyperinsulinism, hypoglycemia, obesity, or metabolic syndrome. The subject suspected of having congenital hyperinsulinism, hypoglycemia, obesity, or metabolic syndrome refers to mammals, including humans, rats, and livestock, that have developed or may develop the relevant disease; however, any subject that can be treated with the glucagon derivative of the present invention or the composition containing it is included without limitation. Furthermore, the subject can be efficiently treated by administering a pharmaceutical composition containing a peptide having activity toward the glucagon receptor of the present invention to an individual suspected of having congenital hyperinsulinism, hypoglycemia, or obesity. Congenital hyperinsulinism, hypoglycemia, or obesity are as described above.
[0949] The method of the present invention may include administering a pharmaceutical composition containing a peptide in a pharmaceutically effective amount. A suitable total daily dose may be determined by the treating physician within the scope of proper medical judgment and may be administered in a single dose or in multiple doses. However, for the purposes of the present invention, it is preferable to apply a specific therapeutically effective dose for a specific patient differently depending on various factors and similar factors well known in the pharmaceutical field, including the type and degree of response to be achieved, the specific composition including whether other preparations are used in some cases, the patient's age, weight, general health condition, gender and diet, time of administration, route of administration and secretion rate of the composition, duration of treatment, and drugs used together or concurrently with the specific composition.
[0950] Meanwhile, although not specifically limited thereto, the above method for preventing or treating metabolic syndrome may be a combination therapy further comprising administering one or more compounds or substances having therapeutic activity against metabolic syndrome.
[0951] Where the term "concurrent use" is used herein, it should be understood to refer to simultaneous, individual, or sequential administration. In the case of sequential or individual administration, the interval between the administration of the second component should be such that the beneficial effects of the concurrent use are not lost.
[0953] Another embodiment of the present invention provides a use of a peptide or isolated conjugate having activity toward the glucagon receptor, or said composition, in the manufacture of a drug (or pharmaceutical composition) for the prevention or treatment of congenital hyperinsulinism, hypoglycemia, obesity, or metabolic syndrome.
[0954] The peptide having activity for the glucagon receptor, the isolated conjugate, the composition, congenital hyperinsulinism, hypoglycemia, obesity, and metabolic syndrome are as described above.
[0956] The present invention will be explained in more detail below through examples. However, these examples are intended to illustrate the invention and the scope of the invention is not limited to these examples.
[0958] Example 1: Production of a cell line showing a cAMP response to glucagon
[0960] PCR was performed using the ORF-corresponding portion of the cDNA of the human glucagon receptor gene (OriGene Technologies, Inc. USA) as a template, and forward and reverse primers of SEQ ID NOs 47 and 48, which contain the EcoRI cleavage site and the XhoI cleavage site, respectively.
[0961] At this time, the PCR reaction was performed by repeating the process of denaturation at 95°C for 60 seconds, annealing at 55°C for 60 seconds, and extension at 68°C for 30 seconds 30 times. The PCR product amplified therefrom was subjected to electrophoresis on a 1.0% agarose gel, and a 450 bp band was eluted to obtain the result.
[0963] Forward primer (Sequence No.: 47):
[0964] 5'-CAGCGACACCGACCGTCCCCCCGTACTTAAGGCC-3'
[0965] Reverse primer (Sequence No.: 48):
[0966] 5'-CTAACCGACTCTCGGGGAAGACTGAGCTCGCC-3'
[0968] The above PCR product was cloned into the known animal cell expression vector x0GC / dhfr to prepare the recombinant vector x0GC / GCGR.
[0969] The above-prepared recombinant vector x0GC / GCGR was transformed into CHO DG44 cells cultured in DMEM / F12 medium containing 10% FBS using lipofectamine, and the cells were selectively cultured in a screening medium containing 1 mg / mL G418 and 10 nM methotrexate. From this, monoclonal cell lines were selected using the restriction dilution method, and among them, cell lines exhibiting an excellent concentration-dependent cAMP response to glucagon were finally selected.
[0971] Example 2: Synthesis of Glucagon Derivatives
[0973] To develop glucagon derivatives with improved physical properties, glucagon derivatives as shown in Table 1 below were synthesized by substituting the amino acid sequence of natural glucagon SEQ No. 1 with negatively and positively charged amino acid residues. The relatives described herein in vitro Activity was measured by the method described in Example 4 below.
[0974] Amino acid sequences of natural glucagon and glucagon derivatives Sequence number Peptide sequence Whether a ring is formed pI In vitro Activity (activity relative to SEQ ID NO. 1, %) Sequence Number: 1 HSQGTFTSDYSKYLDSRRAQDFVQWLMNT - 6.8 100 Sequence No.: 2 HSQGTFTSDYSKYLDCDRAQDFVQWLMNT - 4.56 0.6 Sequence Number: 3 HSQGTFTSDYSKYLDCERAQDFVQWLMNT - 4.66 6.1 Sequence Number: 4 HSQGTFTSDYSKYLDSCDAQDFVQWLMNT - 4.13 < 0.1 Sequence Number: 5 HSQGTFTSDYSKYLDSCEAQDFVQWLMNT - 4.22 0.3 Sequence Number: 6 HSQGTFTSDYSKYLDSCEADDFVQWLMNT - 4.03 < 0.1 Sequence Number: 7 YSQGTFTSDYSKYLDSCEADDFVQWLMNT - 3.71 < 0.1 Sequence Number: 8 YXQGTFTSDYSKYLDSCDAQDFVQWLINT - 3.77 < 0.1 Sequence No.: 9 YXQGTFTSDYSKYLDSCDAQDFVVWLINT - 3.77 < 0.1 Sequence No.: 10 YXQGTFTSDYSKYLDSCDADDFVVWLINT - 3.66 < 0.1 Sequence No.: 11 YXQGTFTSDYSKYLDEKCAKEFVQWLMNT - 4.78 4.6 Sequence No.: 12 YXQGTFTSDYSKYLD E KRA K EFVQWLMNTC ring formation 6.20 56.3 Sequence No.: 13 YXQGTFTSDYSCYLDSRRAQDFVQWLMNT - 4.43 5.2 Sequence No.: 14 YXQGTFTSDYSKYLDCKRAKEFVQWLMNT - 8.12 18.1 Sequence No.: 15 YXQGTFTSDYSKYLCEKRAQDFVVWLMNT - 6.11 1.1 Sequence No.: 16 YXQGTFTSDYSKYLDCRRAQVFVQWLMRT - 9.11 4.2 Sequence No.: 17 YXQGTFTSDYSKYLDCVRAQDFVQWLMRT - 6.03 23.2 Sequence No.: 18 YXQGTFTSDYSKYLDSRRACDFRLWLMNT - 8.15 < 0.1 Sequence No.: 19 YXQGTFTSDYSKYLC E KRA K EFVQWLMNT ring formation 8.12 12.1 Sequence No.: 20 YXQGTFTSDYSKYLD E CRA K EFVQWLMNT ring formation 4.78 299.7 Sequence No.: 21 YXQGTFTSDYSKYLD E KCA K EFVQWLMNT ring formation 4.78 57.8 Sequence No.: 22 YXQGTFTSDYSKYLD E KRC K EFVQWLMNT ring formation 6.20 147.8 Sequence Number: 23 YXQGTFTSDYSKYCD E KRA K EFVQWLMNT ring formation 6.20 76.8 Sequence No.: 24 YXQGTFTSDYSKCLD E KRA K EFVQWLMNT ring formation 6.21 58.0 Sequence Number: 25 YXQGTFTSDYSKYLD E KRA K CFVQWLMNT ring formation 8.12 46.9 Sequence No.: 26 WXQGTFTSDYSKYLD E CRA K DFVQWLMNT ring formation 4.68 1.0 Sequence No.: 27 YXQGTFVSDYSKYLD E CRA K DFVQWLMNT ring formation 4.68 93.6 Sequence No.: 28 WXQGTFVSDYSKYLD E CRA K DFVQWLMNT ring formation 4.68 < 0.1 Sequence No.: 29 YXQGTFTSDYSKCLD E RRA K DFVQWLMNT ring formation 6.15 61.3 Sequence No.: 30 WXQGTFTSDYSKCLD E RRA K DFVQWLMNT ring formation 4.44 0.3 Sequence No.: 31 YXQGTFTSDYSKYLDC K RAK E FVQWLMNT ring formation 8.12 6.3 Sequence No.: 32 -SQGTFTSDYSKYLD E CRA K EFVQWLMNT ring formation 4.78 0.7 Sequence No.: 33 YXQGTFTSDYSKYLDSRRAQDFVQWLMNT - 6.04 108.2 Sequence No.: 34 WXQGTFTSDYSKYCD E RRA K EFVQWLMNT ring formation 6.21 0.2 Sequence No.: 35 YXQGTFTSDYSKYCD E RRA K EFVQWLMNT ring formation 6.2 17.7 Sequence No.: 36 YXQGTFTSDCSKYLD E RRA K EFVQWLMNT ring formation 6.21 9.9 Sequence No.: 37 YXQGTFTSDYSKYLD E RRA K EFVQWLMNTC ring formation 6.21 225.5 Sequence No.: 38 YXQGTFCSDYSKYLD E RRA K EFVQWLMNT ring formation 6.15 167.3 Sequence No.: 39 YXQGTFVSDCSKYLD E RRA K DFVQWLMNT ring formation 6.15 3.7 Sequence No.: 40 YXQGTFVSDYSKYLD E RRA K DFVQWLMNTC ring formation 6.15 40.8 Sequence No.: 41 YXQGTFCSDYSKYLD E RRA K DFVQWLMNT ring formation 6.03 45.2 Sequence No.: 42 YXQGTFCSDYSKYLDSRRAQDFVQWLMNT - 6.03 37.9 Sequence No.: 43 YXQGTFTSDCSKYLDSRRAQDFVQWLMNT - 6.03 1.6 Sequence No.: 44 YXQGTFTSDYSKYLDSRRAQDFVQWLMNTC - 6.21 75.4
[0975] In the sequences listed in Table 1 above, the amino acid labeled X is aminoisobutyric acid (Aib), a non-natural amino acid; the underline below the amino acid symbol indicates the formation of a lactam ring between the side chains of the corresponding amino acid pair; and "-" indicates that there is no amino acid residue at that position. Additionally, in the column regarding ring formation, "-" indicates that no ring is formed in the corresponding sequence.
[0977] Example 3: Measurement of pI of glucagon derivative
[0979] To confirm the improved properties of the glucagon derivative synthesized in Example 2 above, the pI was estimated from the amino acid sequence using the pI / Mw tool (http: / / expasy.org / tools / pi_tool.html; Gasteiger et al., 2003) on the ExPASy server.
[0980] As shown in Table 1 above, while natural glucagon of SEQ ID NO: 1 has a pI of 6.8, some glucagon derivatives according to the present invention have a pI in the range of about 4 to 6. Since these glucagon derivatives have a lower or higher pI than natural glucagon, they can exhibit improved solubility and high stability compared to natural glucagon at neutral pH, etc.
[0981] The glucagon derivative according to the present invention can improve patient compliance when used as a treatment for a target disease such as metabolic syndrome, and is suitable for co-administration with other anti-obesity or diabetes treatments, so it can be usefully used as a treatment for metabolic syndrome including obesity, diabetes, nonalcoholic steatohepatitis (NASH), dyslipidemia, and coronary heart disease.
[0983] Example 4: Measurement of cAMP activity of glucagon derivatives
[0985] The activity of the glucagon derivative synthesized in Example 2 was measured in the cell line containing the human glucagon receptor produced in Example 1. Specifically, after subculturing the transformed cell line three or four times per week, 6 x 10⁴ cells were placed in each well of a 384-well plate. 3 Nine passaged cell lines were inoculated and cultured for 24 hours. Natural glucagon was suspended at 200 nM and glucagon derivatives at 1600 nM, respectively, in HBSS (Hank's Balanced Salt Solution) buffer containing 0.5 mM IBMX (3-isobutyl-1-methylxanthine), 0.1% BSA (Bovine serum albumin), and 5 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). The suspensions were then serially diluted 10 times in fourfold increments and applied to the cells using a cAMP assay kit (LANCE cAMP 384 kit, PerkinElmer), after which the fluorescence values were measured. After measurement, the highest fluorescence value was selected as 100%, and from this, the EC values of the glucagon derivatives were calculated. 50 After calculating the values, they were compared with natural glucagon. The results are shown in Table 1 above.
[0987] Example 5: Preparation of a conjugate comprising a glucagon derivative and immunoglobulin Fc (glucagon derivative-immunoglobulin Fc region conjugate)
[0989] As a representative glucagon derivative, a glucagon derivative prepared in Example 2 above, having a pI value of 6-7 and an in vitro activity of 200% or more, was selected to prepare a conjugate. Specifically, to pegylate the cysteine residue of the glucagon derivative with a 10 kDa PEG having a maleimide group and an aldehyde group at each end, namely maleimide-PEG-aldehyde (10 kDa, NOF, Japan), the reaction was carried out at a low temperature for 1 to 3 hours with a molar ratio of glucagon derivative to maleimide-PEG-aldehyde of 1:1 to 5 and a protein concentration of 3 to 10 mg / mL. At this time, the reaction was performed in an environment where 20 to 60% isopropanol was added to 50 mM Tris buffer (pH 7.5). After the reaction was completed, the above reaction solution was applied to SP sepharose HP (GE healthcare, USA) to purify the cysteine mono-pegylated glucagon derivative.
[0990] Next, the purified mono-pegylated glucagon derivative and immunoglobulin Fc were reacted at a molar ratio of 1:2 to 10 and a protein concentration of 10 to 50 mg / ml at 4 to 8°C for 12 to 18 hours. The reaction was carried out in an environment where 10 to 50 mM sodium cyanoborohydride and 10 to 20% isopropanol were added as reducing agents to 100 mM potassium phosphate buffer (pH 6.0). After the reaction was completed, the reaction mixture was applied to a Butyl sepharose FF purification column (GE healthcare, USA) and a Source ISO purification column (GE healthcare, USA) to purify the conjugate containing the glucagon derivative and immunoglobulin Fc.
[0991] The purity analyzed by reverse phase chromatography, size exclusion chromatography, and ion exchange chromatography after preparation was over 95%.
[0992] Here, a conjugate in which a glucagon derivative and immunoglobulin Fc are linked via PEG is referred to as a 'conjugate containing a glucagon derivative and immunoglobulin Fc', a 'glucagon derivative sustained-release conjugate', or a 'sustained-release glucagon derivative', and these terms may be used interchangeably herein.
[0994] Experimental Example 1: Effects on body weight reduction and insulin sensitivity improvement in high-fat diet-induced obese mice
[0996] For this study, high-fat diet-induced obese mice, which are widely used as animal models of obesity, were used. The body weight of the mice was approximately 50–55 g prior to administration. During the study period, mice were housed in groups of seven and given free access to water. Lights were turned off from 6 PM to 6 AM.
[0997] The test groups fed a high-fat diet were: Group 1: Administration of excipients not containing long-acting glucagon (5 ml / kg, injected once every 2 days) - Control Group (Vehicle), Group 2: GLP-1 analog obesity treatment Saxenda ® Group 3: 50 nmol / kg (injected twice daily), Group 4: long-acting glucagon derivative 1.2 nmol / kg (injected once every 2 days), and Group 4: sitagliptin 49.2 mg / kg (injected once daily), a DPP-4 inhibitor.
[0998] The experiment was concluded on day 28. During the experiment, changes in body weight of mice in each group were measured every two days, and changes in blood glucose were measured before administration and on days 1, 4, 7, 10, 13, 16, 19, 22, 25, and 28 after administration. After the experiment was concluded, fat weight and HOMA-IR were measured.
[0999] As a result of measuring weight change, as can be seen in Figure 1, the sustained-release glucagon derivative (1.2 nmol / kg, administered once every 2 days) was confirmed to show a weight reduction of -34.5% compared to before the start of administration, and the effect was compared to the control group (Vehicle), the GLP-1 analog obesity treatment Saxenda ® It showed superior efficacy compared to the weight loss of -2.6%, -16.3%, and -0.1% observed with the ), and the DPP-4 inhibitor sitagliptin, respectively. As can be seen in Figures 2 (A) and 2 (B), the weight loss appears to be due to a significant reduction in fat mass, and improved insulin sensitivity was also confirmed through HOMA-IR measurement results. Furthermore, based on the fact that no increase in blood glucose occurred during the administration period as shown in Figure 3, it was confirmed that it can demonstrate superior weight loss efficacy compared to other obesity treatments, such as GLP-1 analogs and DPP-4 inhibitors, at an administration dose that does not pose a risk of hyperglycemia caused by glucagon.
[1000] Statistical analysis was performed using one-way ANOVA to compare the excipient group (control group) and the test group.
[1002] The above results suggest that the peptide having activity against glucagon receptors according to the present invention can be used as a preventive or therapeutic agent for various metabolic syndromes, hypoglycemia, or congenital hyperinsulinism.
[1004] Experimental Example 2: Efficacy of co-administration of a sustained-release glucagon derivative and an oral antidiabetic agent in high-fat diet-induced obese mice in weight loss and improvement of insulin sensitivity
[1006] For this study, high-fat diet-induced obese mice, which are widely used as animal models of obesity, were used. The body weight of the mice was approximately 50–55 g prior to administration. During the study period, mice were housed in groups of seven and given free access to water. Lights were turned off from 6 PM to 6 AM.
[1007] The test groups fed a high-fat diet were: Group 1: Administration of excipients not containing long-acting glucagon (5 ml / kg, injected once every 2 days) - Control Group (Vehicle), Group 2: GLP-1 analog obesity treatment Saxenda ® Group 3: 50 nmol / kg (injected twice daily), Group 4: long-acting glucagon derivative 1.2 nmol / kg (injected once every 2 days), Group 5: DPP-4 inhibitor sitagliptin 49.2 mg / kg (injected once daily), Group 5: SGLT-2 inhibitor empagliflozin 12.3 mg / kg (injected once daily), Group 6: concomitant administration of sitagliptin 49.2 mg / kg (injected once daily) and long-acting glucagon derivative 1.2 nmol / kg (injected once every 2 days), and Group 7: concomitant administration of empagliflozin 12.3 mg / kg (injected once daily) and long-acting glucagon derivative 1.2 nmol / kg (injected once every 2 days). The long-acting glucagon derivative used in this experiment is the long-acting derivative according to Example 5.
[1008] The experiment was concluded on day 28. During the experiment, changes in body weight of mice in each group were measured every two days, and changes in blood glucose were measured before administration and on days 1, 4, 7, 10, 13, 16, 19, 22, 25, and 28 after administration. After the experiment was concluded, fat weight and HOMA-IR were measured.
[1009] As a result of measuring weight changes, as confirmed in Figure 4, the combination therapy groups of a sustained-release glucagon derivative (1.2 nmol / kg, administered once every 2 days) and the DPP-4 inhibitor sitagliptin or the SGLT-2 inhibitor empagliflozin showed superior weight reduction efficacy compared to the group administered the sustained-release glucagon derivative alone, with reductions of -46.9% and -39.5%, respectively, compared to pre-administration levels. This effect was compared to the control group (Vehicle) and the GLP-1 analog obesity treatment Saxenda ®It showed superior efficacy compared to the weight loss of -2.6%, -16.3%, -0.1%, and -10.4% observed with the DPP-4 inhibitor sitagliptin and the SGLT-2 inhibitor empagliflozin, respectively. As can be seen in Figures 5 (A) and 5 (B), the weight loss appears to be due to a significant reduction in body fat, and improved insulin sensitivity was also confirmed through HOMA-IR measurements. Furthermore, based on the fact that no increase in blood glucose occurred during the administration period as shown in Figure 6, it was confirmed that it can demonstrate superior weight loss efficacy compared to other obesity treatments, such as GLP-1 analogs and DPP-4 inhibitors, at an administration dose that does not pose a risk of hyperglycemia caused by glucagon. Furthermore, it was confirmed that when administered in combination with oral diabetes medications such as the DPP-4 inhibitor sitagliptin and the SGLT-2 inhibitor empagliflozin, not only can an enhanced obesity treatment effect be expected through additional weight loss, but an improvement in blood glucose levels can also be expected by improving insulin sensitivity.
[1010] Statistical analysis was performed using one-way ANOVA to compare the excipient group (control group) and the test group.
[1012] Experimental Example 3: Confirmation of body weight reduction and additional efficacy of co-administration of sustained-release glucagon derivatives and sustained-release GLP-1 analogs in high-fat diet-induced obese mice
[1014] For this study, high-fat diet-induced obese mice, which are widely used as animal models of obesity, were used. The body weight of the mice was approximately 50–55 g prior to administration. During the study period, mice were housed in groups of seven and given free access to water. Lights were turned off from 6 PM to 6 AM.
[1015] The test groups fed a high-fat diet were: Group 1: Administration of excipients not containing long-acting glucagon (5 ml / kg, injected once every 2 days) - Control Group (Vehicle), Group 2: GLP-1 analog Saxenda ®) 50 nmol / kg (injection twice daily), Group 3: Long-acting GLP-1 analog Ozempic ® ) 20.5 nmol / kg (injection once every 2 days), Group 4: Long-acting GLP-1 analog Trulicity ® ) 2.7 nmol / kg (injection once every 2 days), Group 5: Long-acting glucagon derivative 2.0 nmol / kg (injection once every 2 days), Group 6: GLP-1 analog Saxenda ® ) Concomitant administration of 50 nmol / kg (injection twice daily) and long-acting glucagon derivative 2.0 nmol / kg (injection once every 2 days), Group 7: Long-acting GLP-1 analog Ozempic ® ) Co-administration of 20.5 nmol / kg (injection once every 2 days) and a long-acting glucagon derivative 2.0 nmol / kg (injection once every 2 days) and Group 8: Long-acting GLP-1 analog Trulicity ® There is a combination of 2.7 nmol / kg (injection once every 2 days) and a sustained-release glucagon derivative 2.0 nmol / kg (injection once every 2 days). The sustained-release glucagon derivative used in this experiment is the sustained-release derivative according to Example 5.
[1016] The experiment was concluded on the 28th day, and during the experiment, changes in body weight of mice in each group were measured every two days. After the experiment was concluded, blood lipid levels, fat weight, and blood glucose were measured.
[1017] As a result of measuring body weight changes, as can be seen in Figure 7, the glucagon sustained-release derivative (2.0 nmol / kg, administered once every 2 days) and the GLP-1 analog Saxenda ® ), sustained-release GLP-1 analog Ozempic ® ) and the sustained-release GLP-1 analog Trulicity ®Each combination therapy group showed weight loss of -47.54%, -45.71%, and -43.68% compared to pre-administration levels, respectively, demonstrating superior weight loss efficacy compared to the -39.88% weight loss of the glucagon long-acting derivative monotherapy group; this effect was compared to the control group (Vehicle) and the GLP-1 analog obesity treatment Saxenda ® ) Long-acting GLP-1 analog Ozempic ® ) and the sustained-release GLP-1 analog Trulicity ® It was superior to the weight loss amounts of 1.34%, -18.10%, -12.38%, and -3.81% shown in, respectively.
[1018] In addition, as can be seen in Figures 8(A) and (B), fat reduction and improvement in blood lipid levels were additionally confirmed, similar to the effect of weight loss.
[1019] Furthermore, based on the fact that no increase in blood glucose occurred during the administration period as shown in Fig. 9, it was confirmed that glucagon can demonstrate superior weight loss efficacy compared to other obesity treatments, such as GLP-1 analogs, at dosages that do not pose a risk of hyperglycemia caused by glucagon. Moreover, it was confirmed that when administered in combination with GLP-1 analogs, an enhanced obesity treatment effect can be expected through additional weight loss.
[1020] Statistical analysis was performed using one-way ANOVA to compare the excipient group (control group) and the test group.
[1022] The above results suggest that the combined use of a substance or conjugate thereof having activity toward glucagon receptors according to the present invention and a compound or substance having therapeutic activity toward metabolic syndrome can be used as a preventive or therapeutic agent for metabolic syndrome.
[1024] From the foregoing description, those skilled in the art to which the present invention pertains will understand that the present invention may be implemented in other specific forms without altering its technical concept or essential features. In this regard, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as including all modifications or variations derived from the meaning and scope of the claims set forth below and their equivalents, rather than from the detailed description above.
Claims
Claim 1 A combination for the prevention or treatment of metabolic syndrome comprising (i) a substance having activity toward a glucagon receptor or a conjugate thereof and (ii) a compound or substance having therapeutic activity toward metabolic syndrome, wherein the substance having activity toward a glucagon receptor is a peptide having an amino acid sequence of any one of SEQ ID NOs 20, 22, 33, 37, and 38, and the conjugate is a biocompatible material bound to the substance having activity toward a glucagon receptor, and the biocompatible material is selected from the group consisting of albumin, FcRn conjugate, fibronectin, transferrin, heparin, and elastin, and the compound or substance having therapeutic activity toward metabolic syndrome is a GLP-1 (glucagon-like peptide-1) receptor agonist, a DPP-IV (dipeptidyl peptidase-IV) inhibitor, biguanides, sulfonylureas, The above is selected from the group consisting of meglitinide, thiazolidinedione (TZD), and SGLT2 (sodium-glucose cotransporter) inhibitors, the above GLP-1 receptor agonist is any one selected from the group consisting of lixisenatide, dulaglutide, liraglutide, semaglutide, albiglutide, and taspoglutide, the above DPP-IV inhibitor is any one selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin, anagliptin, teneligliptin, trelagliptin, gemigliptin, omagliliptin, evogliptin, and deutogliptin, and the above SGLT2 (sodium-glucose cotransporter) inhibitor is empagliflozin, dapagliflozin, Canagliflozin, Remogliflozin, Remogliflozin Ethabonate, Sergliflozin, Ipragliflozin, Topogliflozin, Luceogliflozin,A combination selected from the group consisting of and ertugliflozin, wherein the FcRn binding substance is a polypeptide comprising an immunoglobulin Fc region. Claim 2 In claim 1, the peptide is a combination having a pI different from 6.8, which is the pI of natural glucagon. Claim 3 A combination according to claim 1, wherein a ring is formed between each amino acid in the pair of the 16th and 20th amino acids of the peptide, or the pair of the 17th and 21st amino acids. Claim 4 A combination according to claim 1, wherein the C-terminus of the peptide is amidated. Claim 5 In claim 1, the C-terminus of the peptide is an unmodified combination. Claim 6 In claim 1, the peptide is a derivative of natural glucagon capable of activating glucagon receptors. Claim 7 A combination according to claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO. 37 or 38. Claim 8 A combination according to claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO.
37. Claim 9 In claim 1, the substance having activity for the glucagon receptor and the biocompatible substance are combined by being connected to each other through a linker. Claim 10 In claim 9, the linker is a combination selected from the group consisting of peptides, fatty acids, sugars, high molecular weight polymers, low molecular weight compounds, nucleotides, and combinations thereof. Claim 11 In claim 10, the polymer is a combination selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, hyaluronic acid, oligonucleotide, and combinations thereof. Claim 12 In claim 9, the above linker is a combination of polyethylene glycol. Claim 13 In claim 1, the immunoglobulin Fc region is a non-glycosylated combination. Claim 14 The combination according to claim 1, wherein the immunoglobulin Fc region is selected from the group consisting of (a) a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain; (b) a CH1 domain and a CH2 domain; (c) a CH1 domain and a CH3 domain; (d) a CH2 domain and a CH3 domain; (e) a combination of one or more domains among the CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain with an immunoglobulin hinge region or a part of a hinge region; and (f) a dimer of each domain of the heavy chain constant region and the light chain constant region. Claim 15 In claim 1, the polypeptide comprising the immunoglobulin Fc region is a combination in a dimeric form. Claim 16 In claim 1, the immunoglobulin Fc region is a derivative of natural Fc in which a site capable of forming disulfide bonds is removed, some amino acids at the N-terminus of natural Fc are removed, a methionine residue is added to the N-terminus of natural Fc, a complement binding site is removed, or an ADCC (antibody dependent cell mediated cytotoxicity) site is removed. Claim 17 A combination according to claim 1, wherein the immunoglobulin Fc region is an Fc region derived from an immunoglobulin selected from the group consisting of IgG, IgA, IgD, IgE, and IgM. Claim 18 In paragraph 33, the above-mentioned immunoglobulin Fc region is an IgG4 Fc region. Claim 19 A combination according to claim 1, wherein the immunoglobulin Fc region is a non-glycosylated Fc region derived from human IgG4. Claim 20 In item 10, the linker is a combination connected to the cysteine residue of the peptide. Claim 21 In claim 10, the linker of the said conjugate is a combination in which one end is connected to the peptide and the said biocompatible material by a covalent bond formed by reacting with the amine group or thiol group of the biocompatible material and the other end of the linker with the amine group or thiol group of the peptide, respectively. Claim 22 In claim 1, the metabolic syndrome is a combination selected from the group consisting of impaired glucose tolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, nonalcoholic steatohepatitis (NASH), arteriosclerosis due to dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease (coronary heart disease), and stroke. Claim 23 A pharmaceutical composition for the prevention or treatment of metabolic syndrome comprising a combination of any one of claims 1 to 22. Claim 24 A pharmaceutical composition for the prevention or treatment of metabolic syndrome comprising a substance having activity toward a glucagon receptor or a conjugate thereof, characterized by being used in combination with a compound or substance having therapeutic activity toward metabolic syndrome, wherein the substance having activity toward a glucagon receptor is a peptide having an amino acid sequence of any one of SEQ ID NOs 20, 22, 33, 37, and 38, and the conjugate is a biocompatible material bound to the substance having activity toward a glucagon receptor, and the biocompatible material is selected from the group consisting of albumin, FcRn conjugate, fibronectin, transferrin, heparin, and elastin, and the compound or substance having therapeutic activity toward metabolic syndrome is a GLP-1 (glucagon-like peptide-1) receptor agonist, a DPP-IV (dipeptidyl peptidase-IV) inhibitor, a biguanide, The above is selected from the group consisting of sulfonylureas, meglitinide, thiazolidinedione (TZD), and SGLT2 (sodium-glucose cotransporter) inhibitors, the above GLP-1 receptor agonist is any one selected from the group consisting of lixisenatide, dulaglutide, liraglutide, semaglutide, albiglutide, and taspoglutide, the above DPP-IV inhibitor is any one selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin, anagliptin, teneligliptin, trelagliptin, gemigliptin, omagliptine, evogliptin, and deutogliptin, and the above SGLT2 (sodium-glucose cotransporter) inhibitor is Empagliflozin, Dapagliflozin, Canagliflozin, Remogliflozin, Remogliflozin Ethabonate, Sergliflozin, Ipragliflozin, Topogliflozin, Luceogliflozin,A pharmaceutical composition selected from the group consisting of and ertugliflozin, wherein the FcRn binding substance is a polypeptide comprising an immunoglobulin Fc region. Claim 25 A pharmaceutical kit for the prevention or treatment of metabolic syndrome comprising (i) a substance having activity toward a glucagon receptor or a conjugate thereof and (ii) a compound or substance having therapeutic activity toward metabolic syndrome, wherein the substance having activity toward a glucagon receptor is a peptide having an amino acid sequence of any one of SEQ ID NOs 20, 22, 33, 37, and 38, the conjugate is a biocompatible material bound to the substance having activity toward a glucagon receptor, the biocompatible material is selected from the group consisting of albumin, FcRn conjugate, fibronectin, transferrin, heparin, and elastin, and the compound or substance having therapeutic activity toward metabolic syndrome is a GLP-1 (glucagon-like peptide-1) receptor agonist, a DPP-IV (dipeptidyl peptidase-IV) inhibitor, biguanides, The above is selected from the group consisting of sulfonylureas, meglitinide, thiazolidinedione (TZD), and SGLT2 (sodium-glucose cotransporter) inhibitors, the above GLP-1 receptor agonist is any one selected from the group consisting of lixisenatide, dulaglutide, liraglutide, semaglutide, albiglutide, and taspoglutide, the above DPP-IV inhibitor is any one selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin, anagliptin, teneligliptin, trelagliptin, gemigliptin, omagliptine, evogliptin, and deutogliptin, and the above SGLT2 (sodium-glucose cotransporter) inhibitor is Empagliflozin, Dapagliflozin, Canagliflozin, Remogliflozin, Remogliflozin Ethabonate, Sergliflozin, Ipragliflozin, Topogliflozin, Luceogliflozin,A pharmaceutical kit selected from the group consisting of and ertugliflozin, wherein the FcRn binding substance is a polypeptide comprising an immunoglobulin Fc region.
